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General introdUCtion and oUtline
Parts of this introduction have been published as
vriezinga sL, schweizer JJ, Koning f, mearin mL
coeliac disease and gluten-related disorders in childhood





Coeliac disease is an immune-mediated systemic disorder elicited by gluten in genetically 
susceptible individuals, characterized by the presence of a variable combination of gluten-
dependent clinical manifestations, coeliac-disease-specific antibodies, HLA-DQ2 or HLA-
DQ8 haplotypes and enteropathy.[1] In coeliac disease, gluten peptides activate T cells that 
mediate a self-perpetuating inflammatory process. This process leads to mucosal damage 
of the small bowel and other organs, producing symptoms ranging from malabsorption 
with diarrhoea, abdominal distension and weight loss, to nonspecific signs and symptoms 
such as fatigue, osteoporosis or iron deficiency anaemia (Box 1).[1]
Childhood coeliac disease is a common disorder, with a 1–3% prevalence in the general 
Western population that includes the USA, corresponding to about 5 million people in the 
European community, the highest frequency of which resides in Sweden.[2] Therefore, 
coeliac disease might be considered a public health problem in both Europe and the USA.
[2, 3] Coeliac disease is also frequent in South America,[4, 5] the Middle East, North Africa 
and India, where wheat has been the major staple food for centuries, but rare among native 
Africans, Japanese and Chinese people.[6-8] A high index of suspicion for coeliac disease 
should be maintained in all developing countries in children who present with chronic 












macrocytic anaema (folic acid and/or vitamin B12 deficiency)
dermatitis herpetiformis
dental enamel hypoplasia














Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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diarrhoea and malnutrition.[9] Despite the increasing numbers of positive diagnoses for 
coeliac disease, the condition is frequently unrecognized, possibly due to its variable clini-
cal presentation and symptoms,[10, 11] such that for every one child diagnosed with coeliac 
disease, there are seven who remain undiagnosed.[12-14] Coeliac disease can also affect 
extraintestinal organs. In fact, nongastrointestinal manifestations are now more common in 
children than before, possibly because of a greater awareness of symptom diversity.[1, 15] 
Coeliac disease can occur at any age. Patients with other autoimmune diseases, including 
type 1 diabetes mellitus, autoimmune thyroid disease, or patients with selective IgA defi-
ciency, as well as those with Down syndrome, Turner syndrome and Williams syndrome, 
have an increased risk of developing coeliac disease (Box 2).[1]
Box 2. conditions associated with childhood coeliac disease.
type i diabetes mellitus: 3-12%
Selective IgA deficiency: 2-8%
Autoimmune thyroiditis: ≤7%
down, turner, Williams syndrome: 2-12%
first-degree relative with coeliac disease: 2-20%
% prevalence listed for each condition.[1]
PatHoGenesis
Virtually all patients with coeliac disease express the HLA-class II molecules HLA-DQ2 
and/or HLA-DQ8, and gluten-specific HLA-DQ2/8-restricted CD4+ T cells can be isolated 
from their small bowel mucosa.[16] Wheat gluten is composed of different gliadins and 
glutenins; immunogenic epitopes have been identified in all these proteins.[17-25] Some 
of these epitopes found in the α-gliadins and ω-gliadins, barley hordeins and rye secalins, 
are more immunodominant as they trigger T cell responses in almost all patients.[17-19, 
21, 22] Typically, these epitopes are proline-rich, which render them resistant to enzymatic 
degradation.[19] Moreover, they contain an amino acid sequence wherein the glutamine 
(Q) can be modified into glutamic acid (E) by the enzyme transglutaminase type 2 (TG2), 
thereby introducing a negative charge required for high-affinity binding to HLA-DQ2 and 
recognition by CD4+ T cells (figure 1).[26-28]
In coeliac disease, there is a strong HLA-DQ gene-dose effect: HLA-DQ2 homozygous 
individuals have a much higher risk of developing coeliac disease than those who are het-
erozygous.[29] This effect correlates with stronger T cell responses to gluten peptides when 
presented by HLA-DQ2 homozygous cells, indicating that the level of gluten presentation 
influences the risk of disease development.[30] Interestingly, there are no indications for 




and severity of intestinal lesions in childhood coeliac disease are similar in HLA-DQ2 ho-
mozygous and heterozygous individuals.[31] Apparently, once tolerance is lost, the level of 
antigen presentation in the intestine is sufficient to sustain the inflammatory gluten-specific 
Cd4+ T cell response.[30, 32] This process might relate to the local production of IFN-γ by 
these Cd4+ T cells, widely known to enhance HLA expression on antigen-presenting cells.
[30] After the disease-causing gluten-specific T cell response in the lamina propria, major 
changes occur in the composition, size and activation state of the intraepithelial lymphocyte 
(IEL) compartment in patients with coeliac disease.[33] Normally, IELs are found scattered 
throughout the intestinal epithelium and are located at the basolateral side of the epithelial 
cell layer. Although the majority of IELs are CD8+αβ T cell receptor (TCR)+ T cells, higher 
numbers of both Cd8+αβtCr+ and tCrγδ+ T cells are found in patients with coeliac disease 
than in healthy individuals (figure 1).[32, 34] Moreover, IELs are found at the tip of the villi 
in coeliac disease, indicating a redistribution of the IELs in the epithelium, not observed in 
healthy individuals.[35] Although the importance of the increased number of TCRγδ+ T cells 
in coeliac disease remains unclear, CD8+αβtCr+ T cells gain a natural-killer-like phenotype, 
suggesting that they might be involved in the epithelial cell killing and remodelling observed 
in active coeliac disease.[36] IL-15 has a key role in coeliac disease as it is overexpressed by 
the epithelial cells and can directly activate adjacent IELs.[36, 37] In addition, it is feasible 
Figure 1 schematic representation of the immune response to gluten peptides in the small bowel mucosa 
of patients with coeliac disease. abbreviations: aPc, antigen-presenting cell; dc, dendritic cell; dGPa, anti-
deamidated gliadin peptide antibody; ieL, intraepithelial lymphocyte; nKG2d, nKG2-d type ii integral mem-
brane protein; tcr, t-cell receptor; tG2, transglutaminase 2; tG2a, anti-transglutaminase type 2 antibody.
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that cytokines released by adaptive T cells in the lamina propria, such as IL-2 and IL-21, 
can reach the epithelial compartment and contribute to the activation of IELs. Thus, the 
changes in the epithelial compartment could be secondary to the activation of CD4+ gluten-
reactive T cells in the lamina propria. Alternatively, it is possible that intrinsic aberrations in 
the epithelial layer cause the observed characteristic changes. Strikingly, the number of 
Cd8+ααtCr+ T cells normalizes but the numbers of TCRαα+ T cells remain elevated. The 
tCrαα+ T cells do not seem to have a pathogenic role upon initiation of a gluten-free diet 
(GFD) but, rather, might be required to maintain epithelial homeostasis.[38]
Next to adaptive IELs, the epithelium also has at least four subsets of innate lymphocytes.
[38] Little is known about the function of these innate lymphoid subsets that are present 
in high numbers in children, especially in young children, but far less so in healthy adults 
and in adults with coeliac disease. One of these subsets bears a resemblance to the IFN-γ-
secreting type 1 innate lymphoid cell (ILC1), the innate homologue of CD4+ tH1 helper cells 
whereas another, the lineage-negative IEL, has a distinct phenotype responsive to IL-15.[38] 
The latter is the likely precursor to the aberrant monoclonally expanded cells in patients 
with refractory coeliac disease type 2: a premalignant condition unresponsive to a GFD that 
is very rare in children.[38] In addition to these genetic and immunological factors, environ-
mental factors including elective Caesarean section, perinatal and childhood infections, 
the use of antibiotics and PPIs, and changes in the microbiota might have a role in the 
pathogenesis of coeliac disease.[39, 40]
diaGnosis
The key to the diagnosis of coeliac disease in children is a high degree of awareness of its 
wide spectrum of symptoms (Box 1). Coeliac disease is thereby diagnosed through a com-
bination of techniques: detection of coeliac-disease-specific autoantibodies, HLA-DQ typ-
ing and small bowel biopsies that are performed while the patient is on a gluten-containing 
diet.[1]
Clinical presentation
The clinical presentation of childhood coeliac disease is partially age-dependent. Very 
young children (<3 years) present more commonly with chronic diarrhoea, abdominal dis-
tension and growth retardation whereas older children and adolescents (≤18 years) present 
with milder gastrointestinal symptoms such as recurrent abdominal pain, vomiting or con-
stipation. Extraintestinal symptoms such as arthritis, neurological symptoms and anaemia 




In the serum, specific coeliac disease autoantibodies are detected against TG2 (TG2A), 
endomysium (EMA), and deamidated gliadin peptides (DGPA).[1] In the case of severe 
histological small bowel alterations, IgA TG2A and EMA have high sensitivities (98% and 
90%, respectively) and specificities (97% and 98%, respectively).[42] In those with less severe 
intestinal damage, these specificity and sensitivity values are lower.[42] Total IgA measure-
ment is also important because coeliac disease is associated with selective IgA deficiency.
[43] In IgA deficiency, IgG coeliac disease antibodies, among which IgG DGPA is most suit-
able, should be determined. IgG DGPA has diagnostic values comparable to those of IgA 
TG2A.[42]
HLA-typing
HLA-typing is not advised in the routine diagnosis of coeliac disease because 40% of the 
general European and American population carry either one or both of these genes.[44] 
However, HLA-typing is useful to exclude coeliac disease because of its very high nega-
tive predictive value, for example in children who have already started a GFD without prior 
diagnostic tests. HLA-typing is also useful in selecting individuals at risk of coeliac disease 
that need to undergo serological coeliac disease screening. Parents of affected children 
support HLA-typing of their other children to assess the risk of the disease.[45]
Histology
The characteristic histological alterations of the small bowel mucosa in coeliac disease 
are partial to total villous atrophy with crypt hyperplasia and IEL infiltration.[46, 47] These 
alterations are rated according to the Marsh–Oberhuber classification depending on the se-
verity of the lesion: ranging from type 0 (normal) to 4, wherein type 4 describes hypoplastic 
lesions.[46, 47] When interpreting the histological alterations one should take the patient’s 
serology, HLA-typing, and clinical manifestations into account. A Marsh–Oberhuber clas-
sification type 3 (a, b or c), or type 2 if accompanied by specific coeliac disease antibodies, 
support the diagnosis of coeliac disease. The severity of the clinical symptoms does not 
correlate with the severity of the histological alterations. Patients with Marsh–Oberhuber 
type 3c can be asymptomatic.[3, 13, 48] Up until the past few years, the histological exami-
nation of small bowel biopsies was the gold standard for the diagnosis of coeliac disease. 
However, in 2012, the European Society for Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) introduced an exception for a specific group of children (figure 2).[1]
Small bowel biopsies can be omitted in children with clear gastrointestinal symptoms, high 
titres of TG2A (>10 upper limit of normal), positive EMA and HLA-DQ2 and/or HLA-DQ8. 
In all other cases, small bowel biopsies are still mandatory for diagnosis. The results of 
the ongoing prospective study ProCede investigating the performance of the esPGHan 
chapter 1
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guidelines will be important to further define situations in which coeliac disease might be 
diagnosed without biopsies.[49]
manaGement
Coeliac disease can be successfully treated with a GFD, which restores small bowel histology 
and improves clinical complaints in the majority of patients.[43] Adhering to a GFD might seem 
simple, but the abundance of gluten-containing food in the Western diet can be challenging, 
and treatment can considerably affect the child’s quality of life.[50, 51] Once diagnosis is con-
firmed, the child should be referred to a paediatric dietician for in-depth information about 
the necessary dietary treatment. The GFD can have negative nutritional consequences. For 
instance, it has been reported that Italian adolescents with coeliac disease consumed an 
unbalanced diet rich in fat and protein, poor in carbohydrate and deficient in calcium, iron 
and fibre as a result of a GFD.[52] Gluten-containing cereals such as wheat, barley and rye 
are important sources of dietary iron, fibre, calcium, folate and vitamin B12, and treatment 
with a GFD can lead to micronutrient deficiencies.[53, 54] Gluten-free buckwheat or quinoa 
Figure 2 esPGHan algorithm for the diagnosis of coeliac disease in children and adolescents with symp-
toms. abbreviations: +, positive; –, negative; ema; anti-endomysium antibody; esPGHan, european society 
of Paediatric Gastroenterology, Hepatology and nutrition; Gfd, gluten-free diet; oeGd, oesophagogastro-
duodenoscopy; tG2a, anti-transglutaminase type 2 antibody.
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1are naturally rich in group B vitamins,[55] but commercially available gluten-free products 
frequently do not contain the same amount of micronutrients as the often enriched wheat 
flour products that they aim to replace.[56] Non contaminated oats are generally well toler-
ated by the majority of children with coeliac disease. However, a randomized double-blind 
study published in 2014 showed that oats prevent normalization of the intestinal mucosa 
immune status in a substantial fraction of paediatric patients with coeliac disease.[57]
The usual care for children with coeliac disease consists of hospital visits to monitor the 
patient’s response to the diet. Subsequent follow-up is dedicated to assess the child’s 
dietary adherence, well-being and adequacy of growth. Determination of coeliac-disease-
specific antibodies in the serum should be done periodically to monitor regression and 
remission; their levels usually returning to normal within 9–12 months after dietary interven-
tion.[58] Testing for anaemia, iron status and calcium, folic acid, vitamins D and B12 levels at 
diagnosis and at the follow-up visits of patients undergoing treatment is common practice. 
However, evidence is weak for the efficacy and adequacy of this practice as there is limited 
information on the incidence of nutritional deficiencies in patients with treated coeliac dis-
ease. The evidence-based British and Dutch guidelines recommend annual visits whereas 
other evidence-based guidelines, such as the ones from the NIH, ESPGHAN, and the North 
American Society for Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 
do not provide guidance on the matter.[1, 59-62]
noveL tHeraPies
Knowledge of the molecular mechanisms underlying coeliac disease offers opportunities 
to develop alternative treatments to the GFD.[63] The use of enzymes as oral supplements 
to enhance gluten degradation has been extensively studied and could help reduce gluten 
exposure.[64, 65] Alternatively, the generation of blockers to prevent gluten peptide binding 
to HLA-DQ2 has been explored.[66, 67] Similarly, blockade of TG2 would prevent gluten 
modification and the development of a full-blown T cell response to gluten.[68] In addi-
tion, gluten peptide vaccination to re-introduce gluten tolerance has been proposed,[69] 
whereas other studies aim to improve barrier function in the small intestine to prevent the 
entry of gluten peptides into the lamina propria.[70] So far, none of these approaches has 




Previous retrospective studies suggested a ‘window of opportunity’ for primary prevention 
by introducing gluten between 4–6 months of age.[71, 72] Based on the results of these 
studies, ESPGHAN recommended that gluten should not be introduced before 17 weeks 
and not later than 26 weeks of age, preferably concurrent with the period of breastfeeding.
[73, 74] However, at time of giving this recommendation, prospective studies and random-
ized controlled trials investigating this ‘window of opportunity’ were lacking. Most studies 
were retrospective, associated with parental recall bias, and none included quantities of 
gluten administered or randomization.[72, 74-77] At time of initiating this thesis, the true 
influence of early feeding on the development of coeliac disease was controversial.
imProvement of care
Traditional medical care for coeliac patients consists of regular physician visits to evaluate 
patient’s health, weight, height (in children), GFD adherence and coeliac-specific serum 
antibodies.[62, 78] Although important, these measures can be time-consuming. Moreover, 
many patients with coeliac disease do not visit their physician for regular follow-up.[79] The 
limited time allotted for outpatient follow-up also typically restricts comprehensive assess-
ment of a patient’s health-related quality of life and dietary adherence. Previous studies 
in adults with other chronic diseases suggest that e-health can encourage patients to 
improve health care participation and the decision-making process.[80] At time of initiating 
this thesis, studies investigating e-health for follow-up of coeliac disease were lacking.
outLine
in chapter 2, the results of the European multi-centre randomized controlled trial ‘Pre-
ventCD’ are presented. PreventCD studied the influence of infant feeding on the develop-
ment of childhood coeliac disease and explored the possibility of inducing tolerance to 
gluten.
In the following three chapters, new strategies for the improvement of care for children 
and young adults with treated coeliac disease are presented. Chapter 3 studies whether 
patients’ and doctors’ reports on coeliac disease-specific health-related quality of life agree. 
Chapter 4 features the results of the CoelKids study, a multi-centre randomized controlled 
trial evaluating a self-management e-health system for coeliac children and young adults. 
Chapter 5 evaluates the performance of three different commercially available point-of-
17
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1care tests for anti-tissuetransglutaminase in children with treated coeliac disease and 
compares the results against those of serum anti-tissuetransglutaminase measured with 
conventional ELISA.
in chapter 6, the major findings of this thesis are discussed in the light of the current lit-
erature and suggestions for future policy and research are made. The English and Dutch 
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A window of opportunity has been suggested for reducing the risk of coeliac disease by 
introducing gluten to infants at 4 to 6 months of age.
Methods
We performed a multicenter, randomized, double-blind, placebo-controlled dietary inter-
vention study involving 944 children who were positive for HLA-DQ2 or HLA-DQ8 and had 
at least one first-degree relative with coeliac disease. From 16 to 24 weeks of age, 475 
participants received 100 mg of immunologically active gluten daily, and 469 received pla-
cebo. Anti–transglutaminase type 2 and antigliadin antibodies were periodically measured. 
The primary outcome was the frequency of biopsy-confirmed coeliac disease at 3 years of 
age.
Results
Coeliac disease was confirmed by means of biopsies in 77 children. To avoid underestima-
tion of the frequency of coeliac disease, 3 additional children who received a diagnosis 
of coeliac disease according to the 2012 European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition diagnostic criteria (without having undergone biopsies) were 
included in the analyses (80 children; median age, 2.8 years; 59% were girls). The cumulative 
incidence of coeliac disease among patients 3 years of age was 5.2% (95% confidence inter-
val [CI], 3.6 to 6.8), with similar rates in the gluten group and the placebo group (5.9% [95% 
CI, 3.7 to 8.1] and 4.5% [95% CI, 2.5 to 6.5], respectively; hazard ratio in the gluten group, 1.23; 
95% CI, 0.79 to 1.91). Rates of elevated levels of anti–transglutaminase type 2 and antigliadin 
antibodies were also similar in the two study groups (7.0% [95% CI, 4.7 to 9.4] in the gluten 
group and 5.7% [95% CI, 3.5 to 7.9] in the placebo group; hazard ratio, 1.14; 95% CI, 0.76 to 1.73). 
Breast-feeding, regardless of whether it was exclusive or whether it was ongoing during 
gluten introduction, did not significantly influence the development of coeliac disease or 
the effect of the intervention.
Conclusions
As compared with placebo, the introduction of small quantities of gluten at 16 to 24 weeks 
of age did not reduce the risk of coeliac disease by 3 years of age in this group of high-risk 
children. (Funded by the European Commission and others; PreventCD Current Controlled 
Trials number, ISRCTN74582487)
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introduction
Coeliac disease (CD), an immune-mediated systemic disorder elicited by gluten in ge-
netically susceptible persons, is characterized by anti-transglutaminase type 2 antibodies 
(TG2A) and enteropathy.[1] The prevalence of CD is 1-3% in the general population and 
approximately 10% among first-degree family members of patients with CD.[2-10] CD is 
treated with a gluten-free diet. More than 95% of patients have the HLA-DQ2 heterodimer, 
either in the cis or trans configuration. Most of the remaining patients have the HLA-DQ8 
heterodimer or half of the DQ2 heterodimer (DQB1*02).[1, 8, 11-14] However, more than 25% 
of the general population carries these haplotypes,[8, 13] indicating that additional factors 
are involved in disease development. CD increases overall mortality risk,[15] reduces qual-
ity of life,[16] and has extensive negative economic consequences.[17, 18] The health and 
quality of life of patients improves with a gluten-free diet, but primary prevention would be 
more beneficial.[19, 20] Results from observational studies indicate that the development 
of oral tolerance for gluten is initiated early in life, and that the mode of introducing gluten 
to infants may influence the risk of CD in predisposed persons.[21-25] The results of these 
studies suggest that there is a “window of opportunity” at 4 to 6 months of age, when the 
first exposure to gluten should occur in order to decrease the risk of CD.[24, 25] The results 
of studies evaluating breastfeeding and the risk for CD are inconclusive, since most of these 
studies were retrospective and associated with parental recall bias, and none included 
randomization or specified the quantities of gluten consumed.[23-27] At present, the true 
influence of early feeding on the development of CD remains controversial.
To investigate the possible primary prevention of CD, the European multicenter project 
“Prevent Coeliac Disease” (PreventCD; www.preventcd.com) was initiated.[19] It was hypoth-
esized that the frequency of CD at 3 years of age could be reduced by exposing genetically 
predisposed infants to small quantities of gluten at 16 to 24 weeks of age, preferably while 
they were still being breastfed.
metHods
Study design and participants
We performed a prospective, randomized, double-blind, placebo-controlled, dietary-
intervention study. The first child was included on May 26, 2007, and the follow-up for this 
analysis closed on September 10, 2013, when the youngest study participant turned 3 years 
of age; the oldest participants were up to 6 years of age.
chapter 2
28
Infants 0 to 3 months of age were recruited consecutively through CD organizations from 
Croatia, Germany, Hungary, Israel, Italy, the Netherlands, Poland, and Spain. Infants were 
required to have the HLA-DQ2, HLA-DQ8, or HLA-DQB1*02 heterodimer (centrally typed) 
and to have at least one first-degree family member with CD confirmed by means of small-
bowel biopsies. We excluded premature infants and those with trisomy 21 and Turner’s 
syndrome (online supplementary appendix, available at nejm.org).
Intervention
We randomly assigned participants to receive either 200 mg of vital wheat gluten mixed 
with 1.8 g lactose (equivalent to 100 mg of immunologically active gluten), or to placebo 
(2 g lactose), given daily for 8 weeks starting at 16 weeks of age (online supplementary 
appendix). Previous assessment of the vital wheat gluten by means of ELISA and Western 
blot analysis had shown the presence of gluten proteins typically found in wheat gluten. 
Randomization, stratified by participating country, was performed with the use of variable 
block sizes ranging from 4 to 8 and with SPSS software (version 18.0). The investigators and 
the parents of the participants were unaware of the intervention assignments. adherence 
to the study assignment was assessed by means of frequent interviews with the parents 
(online table S1). Participants were considered to have adhered to the intervention assign-
ment if at least 75% of the material was ingested and no additional gluten was consumed. 
After the intervention, parents were advised to introduce gluten gradually, using regular 
products and standardized recommendations (online supplementary appendix).
Outcomes
the primary outcome was the frequency of Cd at 3 years of age. the diagnosis of Cd was 
based on the histologic findings of small-bowel biopsies, according to the 1990 criteria of 
the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN).
[28] Secondary end points were the occurrence of symptoms and the immune response to 
gluten as indicated by elevated serum antibodies associated with CD (anti-gliadin antibod-
ies and TG2A) (online supplementary appendix).
Follow-up and assessment of CD
We periodically monitored health status, anthropometric variables, and feeding habits 
(i.e. breastfeeding and formula feeding), and we quantified gluten consumption[29] using 
standardized questionnaires (online table S1). Measurement of serum antigliadin and TG2A 
were performed centrally at least seven times during the first 3 years of age and then an-
nually thereafter. The parents of children with elevated CD-associated antibodies or with 
symptoms suggesting CD were offered small-bowel biopsies to confirm the diagnosis in 
their child (online supplementary appendix). The biopsy specimens were histologically as-
sessed at the study sites and were also reviewed by an author who is a pathologist.[30] The 
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age of the patient at which the diagnostic biopsies were performed was considered to be 
the age at the diagnosis of Cd.
Study oversight
The study was approved by the medical ethics committee at each participating center and 
complied with the Good Clinical Practices regulations (online supplementary appendix). 
The authors vouch for the veracity and completeness of the data and analyses reported 
and for the adherence of the study to the protocol, available at nejm.org.
From 2007 to 2011, the study did not have commercial support. After 2011, Thermo Fisher 
Scientific performed antibody assessments without charge, and together with Eurospital 
and Fria Bröd, Thermo Fisher Scientific partly funded the project progress meetings. The 
funding organizations had no role in the conception, design, or conduct of the study, in the 
analysis or interpretation of the data, or in the writing of the manuscript of the decision to 
submit it for publication.
Statistical analysis
To detect a 50% reduction in the development of CD in the gluten group at 3 years of age 
(5%, versus 10% with placebo) with a two-sided significance level of 5% and with 80% power, 
we calculated that 474 children would be required in each group.[19]
All the data were entered into a Web-based data management application with the use 
of a central structured-query-language server database (NEN 7510 certified). A statistical 
analysis plan was published online before the randomization codes were opened (http://
preventcd.com/images/stories/Publications/PreventCD_SAP_1_0.pdf, online supple-
mentary appendix). For estimating the cumulative incidence of CD, Kaplan-Meier curves 
were calculated, with time defined as the patient’s age at diagnosis of CD or at the last 
assessment or withdrawal from the study (when data were censored). For comparison, a 
log-rank test (two-sided) was used, stratified according to participating country. The hazard 
ratio for CD in the gluten group, as compared with the placebo group (with 95% confidence 
intervals), is provided, on the basis of a Cox proportional-hazards regression analysis. The 
primary analysis was performed according to the intention-to-treat principle. Differences in 
cumulative incidence of CD were assessed according to the baseline variables by means 
of Cox proportional-hazards regression (multivariate) analysis and according to the duration 
of breast-feeding, daily gluten intake, and occurrence of infection by means of a landmark 
analysis (online supplementary appendix). Different intervention effects were assessed in 
subgroups by including an interaction term between intervention and subgroup in the Cox 





Characteristics of the participants
The parents of 1343 children provided written informed consent for the study. A total of 963 
children were randomly assigned to receive gluten (483 participants) or placebo (480) (fig-
ure 1 and online supplementary appendix). After randomization, the number of children was 
reduced to 944 because 19 children did not fulfill the inclusion criteria. A total of 99 children 
(10.5%) did not adhere to the intervention assignment (59 children in the gluten group and 
40 in the placebo group). A total of 141 children stopped participating before 3 years of age 
(withdrawal rate 14.9%, 69 participants in the gluten group and 72 in the placebo group). A 
total of 59 children withdrew during the first year (6.2%), 49 during the second year (5.2%), 
and 33 during the third year (3.5%); the median follow-up was 4 years (range, 22 days to 6.30 
years). The reasons for withdrawal were unknown for 57% of the children, were related to 
practical issues for 39% (e.g. blood sampling or travel distance to center), and were related 
to adverse events for 4% (online supplementary appendix).
The baseline characteristics of the children were similarly distributed between the interven-
tion groups, with the exception of homozygosity for HLA-DQ2 (Table 1). data on breast-
feeding were available for 943 children: 882 started breast-feeding; at 6 months of age, 527 
(55.8%) were breast-fed, and 265 (28.1%) were breast-fed without complementary feeding 
except for the intervention product. of the 455 mothers with Cd, 431 were consuming a 
gluten-free diet during pregnancy and lactation. Rotavirus vaccination was performed in 211 
children (22.4%), either before the intervention (176 children) or during the intervention (35).
Diagnosis of CD
The numbers of children who met the criteria to undergo small-bowel biopsies are shown 
in figure 1. A total of 101 small-bowel biopsies were performed in 94 children (Table 2, and 
online supplementary appendix). CD was confirmed by means of biopsies in 77 children. 
To avoid underestimation of the frequency of CD, 3 additional children, whose parents 
declined biopsies on behalf of their children but who complied with the 2012 ESPGHAN 
diagnostic criteria,[1] were considered to have CD in all analyses (figure 1).
The median age of the 80 children at diagnosis was 2.8 years (range, 1.1 to 5.6), and all the 
children had an elevated level of TG2A; 59% were girls. The most frequent symptoms were 
abdominal distension (in 20 children) and diarrhea (in 19). The cumulative incidence of CD at 
3, 4 and 5 years of age was 5.2% (95% confidence interval [CI] 3.6 to 6.8), 8.8% (95% CI 6.6 to 
11.0) and 12.1% (95% CI 9.2 to 15.0) respectively (online table S2, online figure S1). CD was sig-
nificantly more frequent in girls; at 3 years of age, the cumulative incidence among girls and 
boys was 7.2% and 3.4%, respectively; at 4 years of age, 11.8% and 6.1%, and at 5 years of age, 
14.5% and 9.9% (p=0.04 by the log-rank test, p=0.02 by multivariate analysis) (online table S2). 
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Figure 1 randomization and diagnosed cases of coeliac disease. a total of 25 children were included in a 
pilot study to test the infrastructure of the study and were not included in the primary analysis. a total of 19 
children underwent randomization in error and were excluded from the study. on the basis of histologic 
results of small-bowel biopsies, active cd was ruled out in 17 children, although 3 of the 17 had potential 
CD. There was no clear diagnosis in 8 asymptomatic children whose parents declined small-bowel biopsies 
on their behalf and who had transient levels of cd–associated antibodies. cd was diagnosed in 3 children 
according to the 2012 european society for Pediatric Gastroenterology, Hepatology, and nutrition diagnostic 
criteria (without having undergone biopsies).[1]
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Table 1 characteristics of the participating children.a
Gluten (n=475) Placebo (n=469)
age (in years) at end of follow-up for this analysis, mean (min-max) 4.9 (3.1-6.5) 5.0 (3.1-6.6)
female sex, no. (%) 228 (48.0) 226 (48.2)
Gestational age (in weeks), mean (min-max) 39.1 (34-43) 39.2 (35-42)
Birth weight (in grams), mean (min-max) 3316 (1730b-5000) 3346 (2000-4740)
country, no. (%) spain 130 (27.4) 119 (25.4)
italy 70 (14.7) 69 (14.7)
Hungary 70 (14.7) 68 (14.5)
the netherlands 67 (14.1) 66 (14.1)
Germany 55 (11.6) 58 (12.4)
israel 47 (9.9) 48 (10.2)
Poland 30 (6.3) 34 (7.2)
croatia 6 (1.3) 7 (1.5)
HLa-risk groupc,
no./total no. (%)
1 80/462 (17.3) 49/449 (10.9)
2 46/462 (10.0) 42/449 (9.4)
3 199/462 (43.1) 218/449 (48.6)
4 29/462 (6.3) 37/449 (8.2)
5 108/462 (23.4) 103/449 (22.9)
first degree relatives with cd, no. 
(%)
1 431 (90.7) 432 (92.1)
2 42 (8.8) 32 (6.8)
3 or more 2 (0.4) 5 (1.1)
Type of first degree relative with CD, 
no. (%)
mother only 200 (42.1) 207 (44.1)
1 sibling 183 (38.5) 184 (39.2)
father only 48 (10.1) 41 (8.7)
Mother and ≥1 sibling 23 (4.8) 23 (4.9)
>1 sibling, but neither parent 12 (2.5) 7 (1.5)
Father and ≥1 sibling 9 (1.9) 5 (1.1)
mother + father 0 2 (0.4)
a the characteristics of the children were similarly distributed between the intervention groups (P < 0.05), 
with the exception of homozygosity for HLa-dQ2 (P = 0.05).
b data included a pair of healthy twins.
c data on the HLa-risk groups were available for 911 of 944 children, with HLa typing performed by means 
of single-nucleotide polymorphisms (SNPs) on the basis of the tag-SNP approach.[8] The HLA risk groups 
were defined as follows: group 1 included DR3–DQ2/DR3–DQ2 (DQ2.5/DQ2.5) and DR3–DQ2/DR7–DQ2 
(dQ2.5/dQ2.2); group 2 dr7–dQ2/dr5–dQ7 (dQ2.2/dQ7); group 3 dr3–dQ2/dr5–dQ7 (dQ2.5/dQ7), dr3–
DQ2/DR4-DQ8 (DQ2.5/DQ8), and DR3–DQ2/other (DQ2.5/other); group 4 DR7–DQ2/DR7–DQ2 (DQ2.2/
DQ2.2), DR7–DQ2/DR4–DQ8 (DQ2.2/DQ8), and DR4–DQ8/DR4–DQ8 (DQ8/DQ8); and group 5 DR7–DQ2/
other (DQ2.2/other), DR4–DQ8/DR5-DQ7 (DQ8/DQ7), and DR4–DQ8/other (DQ8/other); “other” refers to any 
HLA-DQ haplotype except DR3–DQ2, DR7–DQ2, DR4–DQ8, or DR5–DQ7. For the remaining 33 children, the 
status with regard to HLA-DQ2 and HLA-DQ8 positivity was determined by means of the EU-Gen Risk test 
(eurospital), with no information provided regarding the HLa risk group.
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The disease developed significantly more frequently and earlier in the group of children 
who were homozygous for HLA-DQ2 (DR3-DQ2/DR3-DQ2 or DR3-DQ2/DR7-DQ2) than in 
other HLA-risk groups,[4] with cumulative incidence at 3, 4, and 5 years of age of 14.9%, 23.9% 
and 26.9% respectively (p<0.001) (online table S2, online figure S2).
Table 2 distribution of symptoms and coeliac disease (cd) associated antibodies in 94 children with sus-













symptoms as indication for 
biopsy (no.) 52 0 2 13 67
elevated tG2a level as 
indication for biopsy (no.)c 77 5 0 0 82
elevated antigliadin 
antibodies as indication for 
biopsy (no.)*** 12 0 0 6 18
Marsh classification 
of findings in small 
bowel biopsies (no.)d
0 0 4 0 13 17
1 0 1 0 1 2
2 3e 0 2 3 8
3a 18 0 0 0 18
3B 24 0 0 0 24
3c 32 0 0 0 32
4 0 0 0 0 0
a one child with an elevated anti-transglutaminase type 2 antibodies (tG2a) level underwent biopsy three 
times: the histologic findings were normal the first two times but compatible with CD the last time. Five 
children underwent small-bowel biopsies twice. The first time, all had normal histologic findings; the second 
time, two children had normal histologic findings (none had potential CD), and three received a diagnosis 
of cd.
b Potential CD was defined as an elevated level of TG2A and histologic findings in the small bowel.
c An elevated serum level of IgA TG2A was defined as a level of 6 U/ml or more (or in the case of IgA de-
ficiency, an IgG TG2A level of ≥ 10 U/ml). An elevated anti-gliadin antibody level was defined as a level of 
more than 50 U/ml (or in the case of IgA deficiency, an IgG anti-gliadin level of ≥ 17 U/ml) on three occasions 
during a 3-month period, or a level of more than 17 u/ml that was clearly increasing in two tests performed 
during a 3-month period.
d Findings of small-bowel biopsies were assessed according to the Marsh classification,[30] on a scale from 
0 to 4, with classes 0 and 1 being not characteristic of cd, class 2 being compatible with cd only with a con-
comitant elevated tG2a level, classes 3a to 3c being characteristic of cd (with higher letter grades indicat-
ing more villous atrophy), and class 4 being characteristic of refractory cd.
e Three children had a concomitant elevated TG2A level, as compared with the other five children with a 
Marsh classification of 2.[1]
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Figure 2 Cumulative incidence of coeliac disease (CD). A total of 75 of 80 children received a diagnosis of 
cd before 5 years of age. the cumulative incidence of cd in the gluten group versus the placebo group at 
3, 4, and 5 years of age was as follows: 5.9% versus 4.5%, 10.3% versus 7.3%, and 13.5% versus 10.6%, respec-
tively (Panel a). the cumulative incidence among 454 girls in the gluten group and the placebo group was 
as follows: 8.9% versus 5.5%, 15.1% versus 8.5%, and 21.0% versus 8.5%, respectively (Panel B). The cumulative 
incidence among 490 boys was as follows: 3.2% versus 3.6%, 5.9% versus 3.6%, and 7.0% versus 13.4%, re-
spectively (Panel C). The data in Panels B and C show a significant interaction between sex and intervention 
(P=0.01). the insets show the same data on an expanded y axis.
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Breast-feeding did not influence the development of CD. The cumulative incidence at 
3 years of age among children who were not breast-fed, were breastfed for 3 or fewer 
months, were breast-fed for 4 or 5 months, or were breast-fed for 6 or more months were 
7.3%, 4.4%, 8.2% and 4.4%, respectively (p=0.28). Similar cumulative incidences at 3 years of 
age were observed among children who were never exclusively breast-fed or were breast-
fed exclusively for 3 months or less, for 4 or 5 months, and for 6 months or more (5.0%, 9.1%, 
5.3% and 2.7%, respectively; p=0.45). Country of origin and the number and type of affected 
family members were also not related to the development of disease (online table S2), 
nor were rotavirus vaccination, gastrointestinal or respiratory tract infection, and mean daily 
gluten intake (online supplementary appendix).
Development of CD in relation to the intervention
The intervention with gluten, as compared to placebo, did not have a significant effect on the 
frequency of CD development, with cumulative incidences at 3 years of age of 5.9% (95% CI 
3.7 to 8.1) and 4.5% (95% CI 2.5 to 6.5), respectively (p=0.47 by a stratified log-rank test; hazard 
ratio, 1.23; 95% CI 0.79 to 1.9) (figure 2A). The duration of breast-feeding, whether exclusive 
or not, did not significantly influence the effect of the intervention on the development of 
CD (p=0.70 [for exclusive breast-feeding] and p=0.83 [for nonexclusive breast-feeding] for 
interaction; hazard ratios are provided in online table S3).
The cumulative incidence of CD was significantly higher in girls randomly assigned to 
gluten than among those randomly assigned to placebo: at 3 years of age, the incidence 
was 8.9% in the gluten group versus 5.5% in the placebo group (hazard ratio 1.99; 95% CI 1.09 
to 3.65; p=0.02) (figure 2B). This difference was not seen among boys, with frequencies of 
3.2% in the gluten group and 3.6% in the placebo group (hazard ratio 0.62; 95% CI 0.31 to1.24; 
p=0.17; P=0.01 for interaction of sex and intervention) (figure 2C). no other factors than sex 
were found to significantly influence the effect of the intervention on the development of 
Cd (figure 3, online table S3).
The results of the primary per-protocol analysis were similar to those of the intention-to-treat 
analysis (online supplementary appendix). The cumulative incidence of CD seropositivity 
(positive TG2A, positive anti-gliadin antibodies, or both on two occasions during a 3-month 
period) did not differ significantly between the gluten group and the placebo group (7.0% 
[95% CI, 4.7 to 9.4] and 5.7% [95% CI, 3.5 to 7.9], respectively; hazard ratio, 1.14 95% CI, 0.76 
to 1.73; p=0.53) (Table 3, online figure S3). Although elevated levels of TG2A were not found 
in any of the participants at 6 months of age, transient anti-gliadin antibody levels of more 
than 17 U/ml were observed in 59 children in the gluten group and 2 in the placebo group. 





Our results indicate that the early introduction (at 16 weeks of age) of small quantities of 
gluten did not reduce the risk of CD at 3 years of age in genetically predisposed children 
from high-risk families; therefore, our results do not support the protective effect that we 
had hypothesized. In addition, we show that breast-feeding, whether exclusive or not, did 
not have a significant effect on the frequency of CD among these children. In prespecified 
secondary analyses, we observed an association between the early gluten intervention 
Figure 3 Effect of intervention assignment at 16 to 24 weeks of age on the development of coeliac disease 
(CD) in 944 children from high-risk families. Female sex was the only factor to significantly favor placebo 
(P=0.02). The HLA risk groups were defined as follows: group 1 included DR3–DQ2/DR3–DQ2 (DQ2.5/DQ2.5) 
and dr3–dQ2/dr7–dQ2 (dQ2.5/dQ2.2); group 2 dr7–dQ2/dr5–dQ7 (dQ2.2/dQ7); group 3 dr3–dQ2/
DR5–DQ7 (DQ2.5/DQ7), DR3–DQ2/DR4-DQ8 (DQ2.5/DQ8), and DR3–DQ2/other (DQ2.5/other); group 4 
DR7–DQ2/DR7–DQ2 (DQ2.2/DQ2.2), DR7–DQ2/DR4–DQ8 (DQ2.2/DQ8), and DR4–DQ8/DR4–DQ8 (DQ8/
DQ8); and group 5 DR7–DQ2/other (DQ2.2/other), DR4–DQ8/DR5-DQ7 (DQ8/DQ7), and DR4–DQ8/other 
(DQ8/other); “other” refers to any HLA-DQ haplotype except DR3–DQ2, DR7–DQ2, DR4–DQ8, or DR5–DQ7. 
no statistics were computed for children from Poland (64 children) and croatia (13), or for children with three 
or more first-degree relatives with CD (7) because of the low number of children with CD in these groups. The 
black boxes represent the hazard ratio with 95% confidence intervals (horizontal lines); the size of each box 
is proportional to the size of the corresponding subgroup. the overall estimate is represented by the solid 
vertical line; a dashed vertical line representing no effect is also shown.
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and CD in girls but not in boys. We did not find significant effects in the other subgroups 
examined, and the significant finding in girls may be due to chance or to the larger number 
of girls with HLA-DQ2 homozygosity who were randomly assigned to gluten rather than to 
placebo (online table S4). Owing to the small number of children in the different HLA risk 
groups stratified according to sex, we cannot resolve this issue.
The higher frequency of CD among girls than among boys after early exposure to gluten 
may be related to the well-known increased risk of CD among women[13, 31] , but it appears 
too early in life to be related to the protective effect of androgens for autoimmunity.[32] The 
gut microbiota may also play a role in this sexual dimorphism, as was shown recently for 
type 1 diabetes in rodents, in which hormones and microbes together trigger protective 
pathways.[32, 33] Our results also show prospectively the effect of HLA-DQ2 homozygosity 
on the risk of CD in early childhood.
In general, we found no association between the early development of CD and the presence 
of the disease in one or both parents, but this finding should be interpreted with caution, 
Table 3 antibody elevations and diagnosis of coeliac disease (cd) according to intervention assignment.a
variable cumulative incidence P valueb Hazard ratio 
(95% ci)
Gluten (n=475) Placebo (n=469)
%
elevated anti-gliadin at age 6 
months of age
12.4 0.4 <0.001
elevated tG2a at 6 months of age 0.0 (0) 0.0 (0) na




at 1 yr of age 0.9 0.0 0.53 1.14 (0.76-1.73)
at 2 yr of age 3.2 2.1
at 3 yr of age 7.0 5.7
at 4 yr of age 11.5 9.5
at 5 yr of age 14.0 12.1
cd at 1 yr of age 0.0 0.0 0.47 1.23 (0.79-1.91)
at 2 yr of age 2.6 1.9
at 3 yr of age 5.9 4.5
at 4 yr of age 10.3 7.3
at 5 yr of age 13.5 10.6
a na denotes not applicable
b the p-value for the elevated antibody level at 6 months of age was calculated by means of a fisher’s exact 
test, and the other p-values were calculated by means of the log rank test.
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given the small number of fathers with CD in our cohort (105 of 944). Possible explanations 
for the small number of affected fathers are the tendency for mothers to be more involved 
in research projects[34] and the higher frequency of CD among women.[13]
Contrary to previous reports,[35, 36] our data show that determining the TG2A level, but 
not the level of anti-gliadin antibodies, is useful in the assessment of the presence of CD in 
very young children. In fact, we found that symptoms were not prognostic for CD (Table 2), 
indicating that the early determination of the TG2A level in genetically predisposed children 
may offer an opportunity for early diagnosis.[37]
The strength of our study lies in its design as a randomized, double-blind, placebo-con-
trolled trial evaluating a food intervention in a high-risk birth cohort, with comprehensive 
follow-up. The cases of CD were assessed in an identical way, minimizing the risk of bias. 
Nonetheless, our study has some limitations. It may be argued that we introduced gluten in 
a rather artificial way, since 100 mg is approximately 2% of the amount normally introduced 
at weaning.[29] Nevertheless, this quantity has been shown previously to cause histologic 
damage in the intestines of CD patients.[38] After our gluten intervention, levels of anti-
gliadin antibodies were transiently elevated in 59 children at 6 months of age, showing 
that 100 mg of gluten can indeed be immunogenic. Our power calculation was based on 
the assumption of a cumulative incidence of CD of 10% by 3 years of age. We found that 
the actual mean frequency at this age was half the assumed frequency and that it strongly 
depended on sex and HLA haplotype. The confidence intervals for the hazard ratio for the 
effect of the intervention on CD ranged from 0.79 to 1.91, indicating that we were not able to 
rule out a protective effect smaller than 21% or a harmful effect as large as 91%.
Our findings contrast with those from observational studies suggesting that the introduc-
tion of gluten between the ages of 4 to 6 months represents a window of opportunity for 
preventing CD.[23, 24] Much of the information on infant feeding and the risk of CD has 
been obtained from the Swedish CD epidemic, which started in the mid-1980s[21] and was 
related to the introduction of an increased amount of gluten after the age of 6 months, 
when breast-feeding became less common.[9, 22, 23, 39] However, data regarding the 
timing of gluten introduction in relation to breast-feeding, as well as the amount of gluten, 
were obtained retrospectively. Our results also contrast with recent findings in a prospective 
cohort of young children from the general population in Norway.[25] However, that study 
investigated only clinically diagnosed CD, with probable under-reporting of CD, since most 
cases are not clinically recognized. Whereas the observations in the Swedish and Norwe-
gian cohorts are based on the general population from single countries, our results are 
derived from a study population comprising children from high-risk families in 7 European 
countries and Israel. Observational studies involving children with an increased risk for type 
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1 diabetes (positive for HLA-DQ2 or HLA-DQ8) have had controversial results. Although the 
results of a study conducted in the United States support the early introduction of gluten 
at 4 to 6 months of age,[24] the age at gluten introduction did not influence the risk of CD 
autoimmunity in a prospective German birth cohort.[40]
In conclusion, this randomized trial did not show the hypothesized benefit of early exposure 
to small quantities of gluten with regard to reducing the incidence of CD in children from 
high-risk families. In addition, we did not observe a reduced risk of CD associated with the 
maintenance of breast-feeding at the time of gluten introduction. The present European 
guidelines recommend the introduction of small amounts of gluten gradually while the 
child is breast-fed and the avoidance of both the early (<4 months) or late (>7 months) 
introduction of gluten.[41] Our results do not provide evidence to support these guidelines 
or any specific feeding recommendation with respect to the timing of gluten introduction 
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To investigate whether implementation of a coeliac disease (CD)-specific health related 
quality of life (HRQOL) questionnaire would add value to CD follow-up visits; we compared 
patients’ self-reported CD-specific HRQOL with the physician’s report provided during a 
regular CD follow-up visit in children and young adults.
Methods
A cross-sectional study in the control group of a study on self-management in CD (Coel-
Kids). Eligible patients had CD for ≥1year and were ≤25years old. They completed a CD-
specific HRQOL questionnaire (CDDUX) after their regular follow-up visit. Their physicians 
were unaware of the current study’s objectives or self-reported HRQOL. Primary outcome: 
agreement between physician-reported and self-reported HRQOL. Secondary outcomes: 
patient variables predicting a discrepancy between reports, or a lower HRQOL.
Results
Physician-reported HRQOL was available in 70/78 enrolled patients. The self-reported and 
physician-reported HRQOL were concordant in 30/70 (κ=0.093), 6 of them had a poor self-
reported HRQOL. Reports were discrepant in 40/70; all 40 self-reported a poor HRQOL. 
Discrepancies occurred more frequently in patients with a disease duration <9years (32/40 
with discrepant reports were diagnosed <9years ago versus 17/30 with no discrepancy, 
p<0.001) and in females (35/40 with discrepant reports were girls versus 16/30 with no 
discrepancy, p=0.001). Both factors were predictors of a poorer HRQOL.
Conclusions
During regular CD follow-up visits, physicians did not report a poor HRQOL in 40/46 children 
and young adults with a poor self-reported HRQOL. This is consistent with previous studies 
examining other chronic diseases and supports the implementation of self-reported CD-
specific HRQOL measurements in CD follow-up visits.
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introduction
Coeliac disease (CD) is a chronic immune-mediated systemic disorder elicited by gluten 
in genetically susceptible individuals, affecting 1-3% of the general population.[1, 2] The 
disease is treated with a life-long gluten-free diet (GFD).[1, 3] Standard medical care for CD 
patients consists of an evaluation of health status, weight, height (in children), GFD adher-
ence, and CD-specific antibodies in serum.[4] Health-related quality of life (HRQOL) is a 
more subjective and multidimensional concept containing physical, emotional, social, and 
cognitive domains that may vary over time and place.[5, 6] Physicians need to be aware of 
their patients’ HRQOL in order to intervene and facilitate improvement. In previous studies, 
untreated CD was associated with a reduced HRQOL, typically followed by an improve-
ment after initiation of treatment.[7-11] Others found that the HRQOL in treated CD patients 
was still lower compared to that of the general population,[12, 13] or significantly less in 
women with CD.[11, 14-16] The generic HRQOL instruments used in these studies allowed 
for comparison with normative data and across disease populations. Disease-specific in-
struments may be more discriminating and sensitive to small differences and changes.[17] 
In 2008, our research group designed and validated a CD-specific HRQOL questionnaire 
for children and young adults (CDDUX) which has then been used in research settings in 
different countries.[17-19]
While CD-specific HRQOL is an accepted outcome within a research environment, it is often 
not specifically measured during actual follow-up visits in clinical practice. Nevertheless, it 
has been established that in patients with other chronic diseases, the physician overesti-
mates the patient’s HRQOL.[20-22] This has not yet been examined in CD. To investigate 
whether implementation of a CD-specific HRQOL questionnaire would add value to the 
follow-up visits for CD, we compared the self-reported CD-specific HRQOL of a group of 
children and young adults with the physician’s report provided during a regular outpatient 
follow-up visit for CD.
metHods
In this cross-sectional study, we took advantage of the existing control group of the on-
going multicenter research project in the Netherlands, called “CoelKids” (chapter 4).
CoelKids
CoelKids aims to evaluate a multidisciplinary, internet-based, self-management system 
(SMS) for CD-affected children and young adults (≤25 years) to monitor their disease. CD was 
diagnosed according to the ESPGHAN criteria.[3] The date of diagnosis was either the date 
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when small bowel biopsies were performed and/or when positive CD-specific antibodies 
were determined. Patients were included in the study only if CD had been diagnosed for at 
least 1 year, and after informed consent was obtained. Exclusion criteria: IgA deficiency, lack 
of internet access and/or difficulty in comprehending the Dutch questionnaires. Participants 
were randomized into two groups; the SMS group with online evaluations of their health, 
or the control group, wherein patients receive regular outpatient care for CD. The control 
group completed CD-specific HRQOL and GFD adherence questionnaires after their out-
patient consultation. The study protocol was approved by the Medical Ethical Committee of 
the Leiden University Medical Center (LUMC).
Present study
We analysed the HRQOL in the control group of CoelKids participants attending the outpa-
tient clinic of the LUMC. The recruitment period was from May 2012-August 2013. In order to 
accurately reflect the attention given to HRQOL by the physicians during a regular outpatient 
follow-up visit for CD, the physicians received no instructions about how to conduct the 
HRQOL measurement. Furthermore, they were unaware of the study’s objective and the 
patient’s self-reported HRQOL. In “real life” physicians do not use a standardized method 
to assess HRQOL in CD patients. Therefore, the physician-reported HRQOL was extracted 
from the clinical notes in the patient’s Electronic Patient Record (EPR) by a well-instructed 
author who was blinded to the self-reported HRQOL. The physician-reported HRQOL was 
classified as: “1=Good” if the physician reported there were no CD-associated problems (e.g. 
“all is well, GFD accurately followed without problems”); “2=Bad” if CD-associated problems 
were reported; or “0=not recorded” if the physician did not refer to the quality of life.
The self-reported HRQOL was measured online using the CDDUX, validated in Dutch 
children and adolescents.[17] A proxy-version for parents was also available. Thus, the self-
reported HRQOL was either the patient’s own response or his/her parent’s. The CDDUX 
consists of 12 questions divided into 3 subscales: communication (3 items on feelings about 
explaining his/her disease), having CD (3 items on feelings when (s)he is offered gluten-
containing food), and diet (6 items on feelings about dietary restrictions, lifelong aspects).
[17] Response options were given on a 5-point Likert Scale (5=very bad; 1=very good).[17] 
The mean score was calculated to represent an overall evaluation.[17] To compare the self-
reported HRQOL with the physician’s report, the self-reported HRQOL was dichotomized 
into “good” ≤3.00; and “bad” >3.00. Reports were considered discrepant when the dichoto-
mized self-reported HRQOL and the physician-reported HRQOL mismatched.
The patients’ GFD adherence was assessed using the adapted Dutch version of a previously 
validated questionnaire, with scores ranging from 0-3.[23] Patients with scores of 0-1 were 
considered non-compliant. The remaining patients followed a GFD (either with errors [score 
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2] or without errors [score 3]). Patients not adhering to the GFD (score 0-1) were compared 
with the others (score 2-3).
Outcomes
The primary outcome was the agreement between the self- and physician-reported 
HRQOL. Secondary outcomes: (1) the association between a discrepant self- and physician-
reported HRQOL and the following patient variables: gender, patient age, age at diagnosis, 
years since diagnosis, GFD adherence, and whether or not HRQOL was parent-reported; 
and (2) the relationship between the self-reported HRQOL and the aforementioned patient 
variables.
Data-management and statistical analysis
The participants entered their CDDUX responses into a web-based data management ap-
plication (NEN7510 certified). Data collected from the EPR were added manually. A kappa 
value (κ) was computed to assess the agreement between the self- and physician-reported 
HRQOL. The t-test or chi-square test was used to determine the association between the 
aforementioned patient variables and a discrepant self- and physician-reported HRQOL. 
A univariate regression analysis was used to screen for patient variables that potentially 
influenced the self-reported HRQOL. Variables reaching borderline significance (p<0.10) 
were selected for further evaluation in a multivariate model with a backward elimination 
approach. The P-value criteria for inclusion and exclusion were set at 0.05 and 0.10 respec-
tively. This method was repeated for the analysis of the HRQOL scores on the 3 subscales 




the characteristics of the 78 patients are presented in Table 1. Twelve patients self-reported 
to be non-adherent to the GFD: 6 of them consumed normal quantities of gluten (score 0), 
the others made small dietary transgressions (5 regularly [score 0], 1 rarely [score 1]). Out 
of the 66 GFD adherent patients, 1 self-reported committing a dietary error (score 2). The 
parent-proxy version of the CDDUX questionnaire was used by 24/78 patients (mean age 





Self-reported – In general, the HRQOL of the 78 patients ranged from “neutral” to “bad”, with 
a mean score of 3.29 on a scale of 1-5 (1=very good; 5=very bad). Significantly better (lower) 
scores for the subscale communication than for having CD or diet (Table 2) were observed. 
A “bad” or “very bad” HRQOL was reported by 42 patients. A “good” HRQOL was reported 
by 10 patients, while a “very good” HRQOL was reported by 1. Male gender, older age, and 
longer disease duration were identified as predictors of a better HRQOL (univariate analysis, 
p=0.007; 0.042 and 0.010 respectively). Gender and disease duration together explained 
16.7% of the variance in HRQOL (Table 3). The other patient variables did not influence the 
HRQOL. Predictors of a better score on the communication subscale were the male gender 
and using the parent-proxy questionnaire (B=0.561, standard error [SE]=0.224, 95% confidence 
interval [CI]=0.115 to 1.007, p=0.014; and B=0.430, SE=0.215, 95% CI=0.002 to 0.859, p=0.049), 
explaining 12.4% of the variance in the communication score. The only predictor of a better 
score on the having CD subscale was a longer disease duration (B=-0.046, SE=0.015, 95% 
Table 1 Characteristics of the 78 patients with self-reported and physician-reported health related quality 
of life.
age (yrs), mean (min-max) 12.5 (2.2-24.5)
Age ≥18 years, N (%) 13 (16.6)
female, n (%) 57 (73.1)
age at diagnosis of cd (years), mean (min-max) 5.3 (1.0-23.4)
duration of cd (years), mean (min-max) 7.2 (1.0-20.6)
adherent to the Gfda, n (%) 66 (84.6)
cd=coeliac disease
a Gluten free diet (Gfd) score 3 (n=65) or 2 (n=1) measured with the adapted dutch version of a validated 
questionnaire.[23]
Table 2 self-reported health related quality of life (HrQoL)a in 78 children and young adults with coeliac 










all participants 3.29 (0.68) 2.59c (0.92) 3.62 (0.74) 3.48 (0.87)
Patient (n=54) 3.29 (0.73) 2.46c (0.92) 3.64 (0.79) 3.52 (0.92)
Parent-proxy (n=24) 3.31 (0.57)b 2.90b,c (0.88) 3.57b (0.63) 3.39b (0.74)
a a lower score indicating a better HrQoL.
b No significant difference between the total mean HRQOL score reported by patients and parents, nor for 
the scores on the “having CD” and “diet” subscales (Independent samples t-test p=0.872, 0.694,  0.536 re-
spectively) borderline significance for the scores on the “communication” subscale (p=0.048).
c Significant difference between the mean score for “communication” and “having CD” and “communication” 
and “diet” (Related-Samples Wilcoxon Signed Rank Test p≤0.02).
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CI= -0.077 to -0.015, p=0.004), explaining 10.5% of the variance in scores on this subscale. A 
better score on the diet subscale was predicted by a longer disease duration and the male 
gender (B=-0.038, SE=0.018, 95% CI=-0.074 to -0.002, p=0.039; and B=0.461, SE=0.211, 95% 
CI= 0.040 to 0.882, p=0.032), explaining 11.4% of the variance in the score.
Physician-reported – the ePr of 70/78 patients contained information based on which the 
physician-reported HRQOL could be obtained. 6/70 reports on HRQOL were interpreted as 
“bad” because the physician detected problems resulting from the GFD. In the remaining 
64 patients, no CD-related problems were identified, thus, the HRQOL was interpreted as 
“good”. Patient age, age at diagnosis, duration of disease, gender, and adherence to the 
GFD did not influence the physician-reported HRQOL (p=0.137; 0.701; 0.302; 0.930; 0.444 
respectively).
The self-reported HRQOL was dichotomized into “good” for 24 patients and into “bad” for 
46 patients. The physician-reported HRQOL matched the self-reported HRQOL in 30/70 
cases (κ=0.093, Table 4). In the remaining 40 cases, a self-reported “bad” HRQOL was 
incongruously reported by the physician as being “good”. Discrepant reports of HRQOL 
were significantly more frequent in patients who had been diagnosed within the past 9 
years (32/40 patients with discrepant reports diagnosed within past 9 years versus 17/30 
Table 3 Predictors of the health related quality of life (HRQOL) in 78 children and young adults with coeliac 
disease (cd).
univariate analysisa multivariate analysis
B se 95% ci p-value B se 95% ci p-value
intercept nab na na na 2.787 0.308 2.173 –3.401 <0.001
age (years) -0.028 0.014 -0.056 – -0.001 0.042
age at diagnosis 0.008 0.017 -0.027 – 0.043 0.655
duration of cd -0.038 0.014 -0.066 – -0.009 0.010 -0.036 0.014 -0.063 –
-0.008
0.012
female gender c 0.464 0.166 0.133 – 0.795 0.007 0.442 0.161 0.122 – 0.762 0.007
voluntary gluten intake -0.141 0.214 -0.567 – 0.285 0.513
HrQoL reported by 
parent-proxy
0.027 0.168 -0.307 – 0.361 0.872
a By univariate analysis, patient’s age, duration of cd and gender were selected as potential predictors for 
the HrQoL. using a multivariate model with a backward elimination approach, the age of the participant was 
eliminated as a factor influencing HRQOL.
b NA=not applicable because each univariate model has different intercepts.
c male=0, female=1.
comparison of self-reported and physician-reported HrQoL
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in whom the physician-reported HRQOL was correct, p<0.001) and these patients were 
significantly more often female (35/40 patients with discrepant reports were girls versus 
16/30 in whom the physician-reported HRQOL was correct, p=0.001). Age, age at diagnosis 
of CD, adherence to the GFD, and whether or not the HRQOL was assessed by parent-proxy 
was similarly distributed among both groups (p=0.197; 0.899; 0.394 and 0.766 respectively).
discussion
To the best of our knowledge, this is the first study comparing the CD patients’ self-reported 
HRQOL against the physician’s HRQOL reports during a regular outpatient follow-up visit for 
CD. Our results indicate that there is an important discrepancy between these reports since 
in 57% of the patients, the physician had a different perception of the patients’ HRQOL than 
the patient him/herself. What raises concern is that this occurred among patients consid-
ered to be especially vulnerable: those with a “bad” self-reported HRQOL. Our data show 
that this problem occurs significantly more frequently in those who received the diagnosis 
within the past 9 years and in female patients, possibly due to their significantly poorer 
self-reported HRQOL, especially for the “communication” subscale, compared to their male 
counterparts (p=0.014). On the other hand, in patients with a “good” self-reported HRQOL, 
physicians correctly recognized it as being “good”.
The female preponderance in our cohort (73.1%) is a well-known phenomenon in CD.[1] 
Moreover, the neutral to bad self-reported HRQOL in our cohort is comparable with the 
results from previous studies in the Netherlands.[8, 17] Therefore, our cohort may be con-
sidered as representative of the HRQOL of children and young adults with CD in our country. 
In addition, the improvement of the HRQOL as the disease duration becomes longer is 
supported by a previous study.[24] The lower HRQOL found in females has been previously 
described in adults,[11, 14-16] but not in children and/or adolescents.[8, 24, 25] These studies 
Table 4. comparison of the self-reported and physician-reported health related quality of life (HrQoL) of 70a 




Good 24 40 64
Bad 0 6 6
total 24 46 70
a In 8/78 participants, the physician did not assess the HRQOL, self-reported HRQOL was good in n=5 and 
bad in n=3.
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did not use a validated CD-specific HRQOL questionnaire but a generic questionnaire with 
[14, 25] or without [11, 15, 16, 24] added CD-specific questions. In our cohort, compliance with 
the GFD did not influence the self-assessed HRQOL, as was previously described in Dutch 
children whose HRQOL was evaluated in a research setting.[7] Nevertheless, this should 
be interpreted with caution given that a relatively small fraction of patients in our cohort 
were non-compliant to the GFD (12/78). In contrast to our results, literature indicates that 
parents rate their child’s HRQOL lower than the child does him/herself.[17, 18, 24] Owing to 
the design of the larger research project this study is part of, we only had either a patient or 
a parent report, not both. Excluding the 24 participants with parent-reported HRQOL gave 
results similar to those presented in this paper. Furthermore, a recent study with the CDDUX 
in 214 Spanish children showed similar parent- and child-reported scores.[19]
To address the discrepancy between the self-reported and physician-reported HRQOL 
in clinical practice, our results are consistent with previous studies on children affected 
by other chronic diseases.[20-22] One meta-analysis has, in fact, demonstrated that the 
discrepancies between the physician- and child-reported quality of life were mainly found 
in subjective rather than objective domains.[20-22] The CD-specific HRQOL questionnaire 
CDDUX focuses on the subjective matters (feelings).[17] Previous studies do not report 
data on discrepancies between the physician- and self-reported HRQOL based on patient 
variables such as age, disease duration, and gender.
The strength of this study is the use of a previously validated CD-specific HRQOL question-
naire. moreover, the physicians were not informed about this study’s objectives. thus, a 
training effect was excluded, accurately reflecting the attention given to the HRQOL at a 
regular CD follow-up encounter. Indeed, it may be questioned whether each participating 
physician understood the concept of HRQOL similarly, as they did not use a standard-
ized method to assess HRQOL. The physician’s evaluation could have been obtained 
prospectively in a standardized manner. However, our aim was to compare the patient’s 
self-reported HRQOL with the report provided by the physician during regular follow-up. 
Because the latter is typically done without using a standardized method, a question-
naire for physician-reported HRQOL would not provide us with an accurate reflection of 
the attention physicians give to this topic. in addition, assessing whether the outcome of a 
physician-completed HRQOL questionnaire agrees with the real (patient-reported) HRQOL 
would not be of much use, as insufficient time during regular follow-up visits would prevent 
the physician from completing such a questionnaire. Consequently, to investigate whether 
or not the physician’s understanding of the patient’s HRQOL is accurate we extracted the 
physician-reported HRQOL from his/her clinical notes. One may argue that clinical notes 
do not always reflect the physician’s understanding of a patient’s HRQOL. Even if this were 
true, the lack of “poor” HRQOL documentation makes subsequent evaluations difficult and 
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means that measures to increase the HRQOL are not being initiated. Our study included 
all physicians from our institution taking care of coeliac children and young adults. This 
may have introduced inter-observer variability. However, this is a good reflection of real 
life: some physicians may see more coeliac patients than others and some may be more 
focused on HRQOL than others. Nevertheless, we found that the number of discrepancies 
was in fact not influenced by whether the participant was assessed by a paediatric or adult 
gastroenterologist (physician- and self-assessed HRQOL matched in 26/63 participants 
assessed by a paediatrician versus in 4/7 participants assessed by an adult gastroenterolo-
gist, p=0.42) nor by which physician assessed the patient (p=0.67).
Our decision to include a self-reported CD-specific HRQOL score of exactly 3.00 in the 
category with a “good” score may be somewhat artificial. However, including a score of 
3.00 (N=2) into the “bad” category gave results similar to those presented in this paper, as 
well as when all participants with a “neutral” score (2.61-3.40, N=24) were excluded from 
our analysis.[17] Measuring the HRQOL in a clinical setting may generate the expectation 
that the physician can improve the HRQOL.[6] To achieve this in CD is challenging, firstly 
because the GFD is the only effective treatment for CD, and secondly because of the variety 
of factors which impact the generic HRQOL in chronic illness. However, to minimize the 
negative impact of a Gfd and maximize dietary adherence, it is important that the physician 
is aware of the HRQOL of his/her patient. Patients may benefit from a consultation with 
a nutritionist and/or psychologist, or associating with peer-groups. It is possible that the 
results on the self-reported HRQOL vary in different countries. For example, Dutch children 
and adolescents with CD who both have a high general HRQOL, experienced a low to neu-
tral CD-specific HRQOL.[17] In contrast, similarly affected Argentine and Spanish patients 
had good and neutral CD-specific HRQOL scores respectively.[18, 19] Nevertheless, the 
Argentine patients indicated that the CDDUX questionnaire helped them express difficulties 
during the physician visit that otherwise would not have been discussed. Furthermore, their 
physicians indicated that the CDDUX helped them detect aspects that required action, for 
example, the need to refer to a nutritionist or psychologist.[18]
In conclusion, there is a clinically significant discrepancy between the self-reported and 
physician-reported HRQOL in CD-affected children and young adults with a poor self-
assessed HRQOL. Female patients and patients with a more recent diagnosis more often 
had these discrepant reports. Our study supports the implementation of a self-reported 
CD-specific HRQOL measurement in the clinical follow-up of the patients. As the standard 
consultation time allotted for follow-up CD visits is limited, we suggest using a validated 
CD-specific HRQOL questionnaire prior to physician appointments. Sharing the results of 
the questionnaire may improve the patient/parent-doctor communication and the physi-
cians’ understanding of the needs and priorities of children and young adults with CD.
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To evaluate the effectiveness of online consultations for follow-up of children and young 
adults with coeliac disease (CD).
Design
Multicentre randomized controlled trial involving 304 patients aged ≤25 years with CD ≥ 1 year, 
receiving online (N=156) or traditional consultation (N=148). Online consultations included 
symptom questionnaires and home measurements of growth and anti-transglutaminase-
type-2 antibodies (TG2A) using a point-of-care (POC) self-test. Both groups completed 
questionnaires concerning CD-specific health-related quality of life (HRQOL), gluten free 
diet adherence and patient-satisfaction. After 6 months, they performed the POC self-test 
and repeated HRQOL and patient-satisfaction questionnaires. Primary outcome: disease 
control, defined as negative TG2A. Secondary outcomes: CD-specific HRQOL, patient-
satisfaction, costs.
Results
Abdominal pain, lassitude and increased appetite were detected significantly more fre-
quently in the online group than in controls. Growth problems were detected similarly in 
both groups. TG2A was positive in 2 online participants and 13 controls (POC versus labora-
tory, p=0.003). CD-specific HRQOL (1=good;5=poor) was similar in both groups, but improved 
after online consultation (3.25 to 3.16, p=0.013; versus controls 3.10 to 3.23, p=0.810). Patient-
satisfaction (1=low;10=high) was 7.6 in the online group and 8.0 in controls (p=0.001). Mean 
costs in the online group were €202 less than in the control group (p<0.001).
Conclusion
Online consultations for children and young adults with CD are cost-saving and increase 
CD-specific HRQOL. Additionally, patients find these to be satisfactory. The discrepancy 
between the POC test and laboratory results suggests that the used POC test is not sensi-
tive enough to detect low antibody levels and thereby unsuitable to monitor treated CD.
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introduction
Coeliac disease (CD) is an immune-mediated systemic disorder occurring in genetically 
susceptible individuals. It is elicited by gluten ingestion.[1] CD may be considered a public 
health problem, with a prevalence ranging from 1-3% that corresponds to about 5 million 
affected people in the European community.[1-3] Patients are treated with a gluten free 
diet (GFD). This restores small bowel histology and improves clinical complaints in the 
majority.[1, 4] Traditional medical care for CD patients consists of regular physician visits to 
evaluate their health, weight, height (in children), GFD adherence and CD-specific serum 
antibodies.[5, 6] Although important, these measures can be time-consuming. Moreover, 
many patients do not visit their physician for regular CD follow-up.[7] Time constraints dur-
ing outpatient follow-up also typically restrict comprehensive assessments of a patient’s 
health-related quality of life (HRQOL) and dietary adherence. Previous studies in adults with 
other chronic diseases suggest that an online self-management system (SMS) can encour-
age patients to improve health care participation and decision-making process.[8] Patients 
are able to deal with their symptoms, treatment, physical and psychosocial consequences 
and lifestyle changes that are inherent in living with a chronic condition through successful 
disease self-management.[9] We developed an online SMS as a substitute for outpatient 
consultations in the follow-up of CD in children and young adults (CoelKids, www.coelkids.
nl). We hypothesized that disease control in the course of the study would be similar in 
patients using the online SMS and traditional outpatient follow-up.
metHods
Study design and participants
Children and young adults ≤25 years with diagnosed CD ≥1 year prior to recruitment re-
ceived an invitation to participate in this multicentre randomized clinical trial. They were 
recruited between May 2012 and July 2014 from 3 academic and 4 non-academic hospitals 
in the Netherlands. Exclusion criteria were IgA deficiency, no internet access and insufficient 
comprehension of dutch.
Intervention
After written informed consent was obtained, participants were randomized to the online or 
control group, stratified by age at inclusion and gender (figure 1).
The online group used the SMS to replace one traditional outpatient consultation. The 
patients (or parents) were asked to complete a symptom questionnaire (i.e. abdominal pain, 
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weight themselves, which were subsequently plotted on their growth charts and compared 
with previous in-hospital measurements.[10, 11] CD-specific IgA anti-transglutaminase-
type-2 antibodies (TG2A) were self-measured using a commercially available point-of-care 
(POC) test (Biocard Celiac Test, AniBiotech, Vantaa, Finland), validated for detection of IgA 
TG2A.[12-15] It requires 1 drop of fresh blood, obtained by finger-prick. The result (positive/ 
negative) should be interpreted after 10 minutes in a well-lit place. Written instructions were 
sent along with the POC self-test and a video tutorial was available on the study website. 
Participants were requested to e-mail us a picture of the result and to return this test by 
mail. In addition, they completed online questionnaires on GFD adherence, CD-specific 
HRQOL and parents’ and/or patients’ (in the case of young adults) satisfaction with the 
consultation. The researcher discussed the results with the participants (or parents) over 
the telephone, and sent a copy of the results to their physician. In case of abnormalities, an 
outpatient consultation was scheduled.
The control group received traditional care at the outpatient clinic, with their own physician. 
A standardized summary of the consultation’s narrative (symptoms, growth) was used for 
data analysis. TG2A in serum was measured with conventional ELISA (EliAtm Celikeytm iga 
test; ThermoFisher Scientific, Freiburg, Germany) in all participating hospital laboratories. 
Units per millilitre (U/ml) <7 were considered negative, and U/ml ≥7 was positive (measur-
ing range 0.1-≥128 U/ml). After the consultation, participants completed the questionnaires 
concerning GFD adherence, CD-specific HRQOL and patient satisfaction. Their physician 
was blinded to the outcomes of these questionnaires to prevent interference in a traditional 
outpatient consultation.
Six months after baseline, all participants were asked to measure their TG2A levels at home 
using the POC self-test and to respond again to the same CD-specific HRQOL and patient 
satisfaction questionnaires.
Study outcomes
The primary outcome was disease control 6 months after the online or outpatient consul-
tation, defined as negative TG2A results. Secondary outcomes were CD-specific HRQOL, 
patient-satisfaction and costs.
Measures
Abnormal growth was defined as a deviation from the previous annual measurement of at 
least 1 standard deviation (SD) for height/age or for weight/height.
GFD adherence was assessed using the Dutch adaptation of a previously validated ques-
tionnaire.[16] The score ranged from 0-3 (0-1=GFD not followed; 2=GFD followed but with 
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errors; 3=strict GFD). Additionally, participants were asked to agree or disagree with the 
statement, “I follow a strict gluten free diet”.
To assess the CD-specific HRQOL, we used the validated CDDUX questionnaire, consisting 
of 12 questions divided into 3 subscales: communication, diet and having CD.[17] The re-
sponse options were depicted on a 5-point Likert-scale (1=very good; 5=very bad). Usage of 
the parent-proxy version was not determined by patient age. The scores for each subscale 
and the mean overall score were calculated.
Participants rated their satisfaction with the online or outpatient consultation on a scale of 
1-10 (i.e. 1=lowest; 10=highest). We used a combination of items from the Dutch translations 
of the validated Ware’s Patient Satisfaction Questionnaire III (PSQ III, 18 items), Telemedicine 
Satisfaction and Usefulness Questionnaire (TSUQ, 1 item), Parent Satisfaction Survey (PSS, 
3 items) and Dick et al. 1999 (2 items).[18-20] Only items that were applicable to the study 
situation were used. Items were slightly modified to specifically address online or outpa-
tient consultations (supplementary appendix, available from the author upon request). 
Responses were given on a 5-point Likert-scale (1=strongly disagree; 5=strongly agree). Six 
months after baseline, they retrospectively assessed their satisfaction (online table S1B), 
graded on a scale of 1-10.
A cost-minimization analysis was performed from a societal perspective, i.e. factoring in the 
costs of medical care (including physician and patient/parent-initiated consultations during 
the study period) and non-medical costs (e.g. parents’ and/or participants’ work absence, 
travel time/costs). The cost of a resource was valued using standard prices established by 
the Dutch Healthcare Authority (laboratory determinations) and by Hakkaart et al (personnel 
costs).[21] Shipping costs for the online group’s equipment were also included. The time 
spent by the physician during regular consultations, and by the physician-researcher during 
online consultations, was prospectively measured. Participants also kept track of consulta-
tion times.
Ethical consideration
The study protocol was approved by the medical ethics committee of the LUMC and the 
respective boards of participating centres. It complied with Good Clinical Practice guide-
lines. Written informed consent was obtained from participants or their parents/ guardians, 
whenever appropriate. This trial is registered under the Dutch Trial Register NTR3688 (www.
trialregister.nl).
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Data management and statistical analysis
Assuming that an increase in inadequate disease control (positive TG2A) from 20 to 33% 
(equivalence margin 13%) is acceptable in the care of CD patients, 298 patients needed 
to be evaluated with a one-sided alpha of 0.05 and a power of 80%. Taking into account 
a 7.5% loss to follow-up rate, 316 patients had to be enrolled. Participants completed 
the online questionnaires using a data management application (NEN7510 certified). For 
comparison of disease control, HRQOL and satisfaction, the chi-square, Mann-Whitney U 
and armitage’s trend test were used as appropriate. Changes over time within both groups 
were detected with the McNemar and Wilcoxon Signed Rank Test as needed. Generalized 
estimating equations were used to compare costs between both groups. Analyses were 
performed with sPss software (version 23.0).
resuLts
Out of the 680 invited patients, (parents of) 334 (49%) provided written informed consent 
(figure 1). We did not inquire their reasons for refusal. Prior to randomization, 4 patients were 
excluded because they did not meet the inclusion criteria. Consequently, 330 participants 
were randomly assigned to the online (N=165) or control group (N=165). Post-randomization, 
1 participant was excluded because she exceeded the age limit (25.7 years). During the 
project, the number of participants dropped to 304 (online N=156; control N=148) because 
15 participants withdrew their informed consent and another 10 participants became lost to 
follow-up (figure 1). Characteristics of the participants were similarly distributed between 
the online and control group (Table 1). The mean duration between consultation and follow-
up was 6.8 months (standard deviation [SD] 2.5) in the online group and 7.6 months (SD 3.3) 
in the controls (p=0.001).
Table 1 characteristics of the 304 participants with coeliac disease (cd) randomized to the online or control 
group.
online (n=156) Control (n=148)
female – n. (%) 107 (68.6) 97 (65.5)
age in years – mean (min-max) 11.0 (2.6-24.1) 11.4 (2.1-24.5)
age at cd diagnosis in years – mean (min-max) 4.3 (0.9-17.9) 4.9 (1.0-23.4)
disease duration in years – mean (min-max) 6.9 (1.0-20.3) 6.7 (1.0-22.9)
Gluten free diet scorea – n (%) 0-1 12 (7.7) 19 (12.8)
2 2 (1.3) 1 (0.7)
3-4 142 (91.0) 128 (86.5)




Abdominal pain, lassitude and increased appetite were more frequently and significantly 
reported by the online participants than by controls (Table 2). Abnormal growth (weight/
height deviated ≥1SD) was found in 4 online participants and 2 controls. Other growth prob-
lems were detected in 6 participants in the online group: -2SD weight/height growth with 
a deviation of 0.5SD (N=3); -2SD height/age without catch-up growth after CD diagnosis 
(N=2); obesity (N=1); and in 1 control: acceleration in height/age above 2SD (N=1). In general, 
the detection of growth problems was similar in both groups (10 online; 3 controls; p=0.059).
Baseline TG2A results were available in 298/304 participants (online N=153; controls N=145) 
(Table 3). There were significantly more participants with positive TG2A in the control group 
than in the online group: 13/145 (mean titre 21.5 U/ml; range 8-56 U/ml) versus 2/153 (POC 
self-test) (p=0.003). In 3/13 controls with positive TG2A, TG2A continued to decrease since 
the time of CD diagnosis. This was considered normal. Approximately 6 months later, TG2A 
was reassessed with the POC self-test in 279/298 participants with available baseline TG2A 
results (online N=148; control N=131) (Table 3). The number of positive POC self-tests in 
Table 2 frequency of symptoms in 304 participants with self-reported complaints (online group) or reported 
complaints during the consultation with their physician (control group).
online (n=156), n (%) Control (N=148), N (%) p-valuec
abdominal pain no 71 (45.5) 107 (72.3) <0.001
incidentallya 72 (46.2) 38 (25.7)
frequenta 13 (8.3) 2 (1.4)
unknown 0 (0.0) 1 (0.7)
appetite decreased 10 (6.4) 5 (3.4) 0.036
normal 123 (78.8) 135 (91.2)
increased 23 (14.7) 4 (2.7)
unknown 0 (0.0) 4 (2.7)
Lassitude no 90 (57.7) 123 (83.1) <0.001
incidentally 45 (28.8) 9 (6.1)
frequent 18 (11.5) 4 (2.7)
unknown 3 (1.9) 12 (8.1)
defecation constipationb 13 (8.3) 9 (6.1) 0.943
normal 134 (85.9) 132 (89.2)
diarrhoeab 7 (4.5) 3 (2.0)
unknown 2 (1.3) 4 (2.7)
a incidentally = once a week or less; frequent = multiple times per week.
b constipation = 3 or less stools per week; diarrhoea = 3 or more stools per day.
c Using Armitage’s trend test, omitting “unknown” as an answer.
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the online group was similar to baseline (5/148 versus 2/153, p=0.25). In the control group, 
significantly less POC self-tests were positive than laboratory tests at baseline (1/134 versus 
13/145, p=0.012). The single positive POC self-test corresponded to a participant with nega-
tive TG2A at baseline (6 U/ml).
the self-reported dietary adherence assessed with the questionnaire was described 
as “strict” by 142/156 online participants and in 128/148 controls (91% versus 87%, p=0.297) 
(Table 1). out of the 34 patients who were non-adherent to a Gfd according to the question-
naire, 20 patients (8 online; 12 controls) denied gluten consumption by agreeing with the 
statement “I follow a strict gluten free diet” (K=0.50). Positive POC self-tests and serum TG2A 
did not correlate with self-reported gluten consumption as assessed from the question-
naire (K=0.001 and K=-0.024 respectively), nor did these correlate with their answers to the 
statement on strict GFD adherence (K=0.001 and K=-0.008, respectively).
the self-reported CD-specific HRQOL scores are presented in Table 4. Usage of the 
parent-proxy or patient version of the questionnaire was similarly distributed in the online 
Table 3 correlation of iga transglutaminase type 2 antibody (tG2a) results in 304 participants with coeliac 
disease during the baseline consultation (randomized to measurement with point of care [Poc] self-test or 
in hospital laboratory) with results upon reassessment approximately 6 months later with the Poc self-test.













Positive – n. 2 0 0 2 (1.3)
negative – n. 3 143 5b 151 (96.8)
not available – n. 0 0 3c 3 (1.9)
total – n. (% 
reassessed)




Positive – n. 0 10 3d 13 (8.8)
negative – n. 1 120 11e 132 (89.2)
not available – n. 0 3f 0 3 (2.0)
total – n. (% 
reassessed)
1 (0.7) 133 (89.9) 14 (9.4) 148 (100)
aReassessment on average 6.8 months after baseline POC self-test and 7.6 months after hospital laboratory 
measurement.
reasons for test results not being available: banxiety (n=3); technical failure Poc self-test (n=1); unwilling to 
repeat test (n=1); cAnxiety (n=2); unclear instructions (n=1); not enough blood obtained with finger prick (n=1); 
danxiety (n=2); unclear instructions and interpretation results (n=1) ; eanxiety (n=6); unclear instructions (n=3); 
not enough blood obtained with finger prick (n=2); technical failure POC self-test (n=1); unclear interpretation 





















































































































































































































































































































































































































































































































































































































































































































































e-health for coeliac disease
4
and control groups, both at baseline (p=0.41) and at reassessment (p=0.60). During baseline 
consultation, participants’ overall CD-specific HRQOL was similar in both groups (neutral to 
bad) (Table 4). Upon reassessment 6 months later, a statistically significant improvement in 
the overall score was observed in the online group (p=0.013) but not in the controls (p=0.810). 
The improvement concerned the subscales “Communication” and “Diet” (Table 4).
responses to satisfaction with the consultation (grade from 1-10) were available in all 
online participants, in 146/148 of controls at baseline, and 147/148 of controls 6 months 
later. The mean satisfaction was significantly higher in the controls than in the online group 
at baseline (mean grade: 8.16 [range 5-10] versus 7.65 [range 2-10], p<0.001) as well as 6 
months later (mean grade: 8.01 [range 4-10] versus 7.58 [range 3-10], p=0.001). Participants’ 
baseline satisfaction and 6 months later remained uninfluenced by participant age (Spear-
man’s rho online: p=0.362 and p=0.635; controls: p=0.666 and p=0.831) or the duration of CD 
(Spearman’s rho online: p=0.887 and p=0.290; controls: p=0.270 and p=0.437). In comparison 
with online participants, the controls agreed more often to the idea that everything neces-
sary to provide complete medical care was available. They had also reported more often 
that they felt free to discuss anything they found important, while the online group thought 
that the consultation was more impersonal (p<0.001; supplementary table S1). On the other 
hand, online participants found the timing and location of the consultation to be more 
convenient than did the controls (p=0.018 and 0.001 respectively; supplementary table S1). 
Furthermore, 48% (N=75) of the online group regarded the online consultation to be as good 
as outpatient care (disagree N=47; not agree or disagree N=34). In fact, 58% (N=90) wanted to 
continue with online consultations (disagree N=32; not agree or disagree N=34) (supplemen-
tary table S1B). A traditional consultation was preferred by 41% (N=64) of the online group 
(disagree N=61; not agree or disagree N=31). Technical problems were experienced by 31% 
(N=48, no problems N=91; no opinion N=17; supplementary table S1B). The POC self-test was 
preferred to the conventional venepuncture by 80% of the online participants and 81% of the 
controls (supplementary table S2). A conventional venepuncture was preferred because of 
a nurse’s expertise, hospital environment, or the possibility of doing additional blood tests 
(supplementary table S2).
In 29 online participants and 17 controls, abnormalities were detected and further investi-
gated during an extra follow-up consultation (p=0.061). This was because of CD-related 
symptoms in 6 online participants and 2 controls, and growth problems in 10 online partici-
pants (1 also had symptoms) and 3 controls. The 2 online participants with a positive POC 
self-test and the 3 participants with unsuccessful self-tests were referred to the hospital for 
assessment of serum TG2A. Positive serum TG2A was confirmed in 1 participant with a posi-
tive POC self-test. The other participant was already known to have positive serum TG2A and 
did not give consent for reassessment. Out of the 10 controls with abnormal TG2A, 7 were 
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referred to a dietician for dietary assessment. In the other 3 participants, TG2A was only 
slightly positive (8-11 U/ml) and expectant management was provided. A consultation with 
a dietician and/or physician was scheduled for 3/6 online participants with self-assessed 
non-adherence. The other 3 participants declined the offer. In the control group, 3 patients 
Table 5 mean costs per participant made during the study period in the group that was randomly assigned to 
an online consultation for follow-up of coeliac disease (cd) compared with the group assigned to a regular 
outpatient consultation (price level 2015).
Cost categories








Staff costs physician €51 €65 n.a. € -14
iga tG2a €6 €15 n.a. € -9
extra follow-up consultations 







extra follow-up blood work 











travel to consultation and back, 
mean (sd)
n.a. €14 (19) n.a. € -14
duration of consultation for 
participant or parent, mean (sd)
€13 (10) €63 (68) <0.001 € -50
Subtotal non-medical costs, mean (SD) €13 (10) €77 (80) <0.001 € -64
Total, mean (SD) €143 (144) €236 (189) <0.001 € -93
n.a. = not applicable.
a using generalized estimating equations.
details underlying calculation of unit costs incl. overhead en utility costs in euros:
- Staff costs physician: €163.12 per hour (including housing and overhead costs). Mean duration consultation: 
outpatient 0.40 hours (range 0.15-0.78), online 0.31 hours (range 0.10-1.22).
- Point of care test for iga transglutaminase type 2 antibodies (tG2a) €3.50 per unit; preparation €2.22 per 
unit (based on 5 min of work per test for a medical secretary); and sending €0.43 per unit.
- follow-up consultations (physician’s or patient/parent’s initiative) after the outpatient or online consulta-
tion and before the end of participating (~6 months) were considered and included: consultations with the 
physician (outpatient or telephonic), dietician, psychologist/pedagogue, or endocrinologist for problems 
related to growth or thyroid function.
- follow-up blood work (physician’s or patient/parent’s initiative) after the outpatient or online consultation 
and before the end of participating (~6 months) was considered if related to follow-up for cd.
- mean travel distance to the outpatient consultation and back was 26.72 (0-320) km. costs per km: by car: 
€0.22 + €3.33 parking-costs (n=104); by public transport: €0.22 (n=15).
- costs in case leave from work was taken in control group (n=53, mean hours: 3.96 range 1-12 [both parents 
took a day off]): €32.41 per hour. Otherwise in control group (n=95, mean hours 1.87 range 0.17-6.0) and in 
the entire online group (mean hours 0.95 range 0.17-8 [experienced technical problems]): €13.87 per hour.
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were referred to a dietician because of physician-assessed non-adherence to the Gfd (2 of 
them also had positive TG2A). Furthermore, 3 online participants with previously low vitamin 
D or folic acid or previously high thyroid stimulating hormone and anti-thyroid peroxidase 
antibodies were referred to the outpatient clinic. In the same online group, a gluten chal-
lenge was requested by 2 participants (parents doubted the diagnosis) and 1 participant 
was referred to the outpatient clinic because of premature pubarche. Furthermore, extra 
follow-up consultations were scheduled in 4 controls: slightly positive anti-endomysium 
antibodies despite negative TG2A (N=1); failure of TG2A determination (N=1); repeating iron 
determination (N=1); consultation with a social worker (N=1).
In addition, 6 online participants had an extra follow-up consultation because of dissatisfac-
tion with the POC self-test (N=5) or the online consultation (N=1).
mean costs in the online group were €93 lower than in the controls (total costs €143 versus 
€236 [p<0.001]) (Table 5). The non-medical costs of e-health were €64 lower than those 
of the outpatient consultation (p<0.001). The medical costs of the consultations (including 
follow-up visits during the study period) were not significantly different from each other 
(p<0.096) (Table 5). For this calculation, only the TG2A determination (€15.10) determines the 
costs of blood work in the controls. However, complete blood counts and others tests, e.g. 
folic acid, vitamin B12, calcium, alkaline phosphatase and iron status, were also determined 
in the outpatient group, as recommended by the Dutch evidence based CD guidelines.
[6] When taking into account the complete blood work performed during the outpatient 
consultation (on average, €124 per consultation; SD€58), the difference between medical 
costs in the online and outpatient group reached statistical significance (€130 versus €268 
[p<0.001]). In total, mean costs in the online group are €202 lower per participant during the 
study period (medical savings €138; non-medical savings €64).
discussion
Our results indicate that the online consultation for children and young adults with CD is an 
effective and satisfactory instrument for self-management of their disease. To the best of 
our knowledge, this is the first study investigating a self-management intervention in this 
specific population on a physical, psychological, nutritional and economic level. Symptoms 
were recognized significantly more often in the online than the outpatient consultations. 
Abnormal growth was similarly recognized through both approaches. Moreover, online 
consultations increased the CD-specific HRQOL while its mean costs were lower compared 
with the costs of traditional care.
chapter 4
72
The online participants had reported significantly more abdominal pain and lassitude 
than the controls. It is unlikely that such difference occurred by chance but may be partly 
explained by different methods to assess symptoms in both groups. The online group 
responded to a multiple-choice questionnaire while the outpatient participants responded 
to the physician’s verbal questioning. In paediatrics, it has been reported that parents are 
most likely to present the child’s problem to the paediatrician instead of the child him/
herself, and that paediatricians tend to listen more to the parents than the child.[22] In a 
study among asthmatic children, there was a large discrepancy between physician assess-
ment and the child’s description of disease control.[23] In 42% of the children who described 
their asthma as uncontrolled, physicians assessed the asthma to be well-controlled, just as 
73% of the parents reported good control, while their children disagreed.[23] In our study, 
parents accompanied all the (paediatric) controls during outpatient clinic visits. In the online 
group however, 36% of the parents specifically indicated that they had completed the 
consultation together with the child, and 8% of the children had completed it without their 
parents. In the open narratives the parents described the online questionnaire frequently 
initiated a conversation with their child, and that their children told them about symptoms 
parents were not always aware of. This may account for the higher symptom frequency in 
this group.
Results from the POC self-test for TG2A assessment show the used test is unfit for the popu-
lation under study. The used self-test has been validated for CD screening, with reported 
sensitivities and specificities of ≥94% and ≥93%, respectively.[24, 25] However, its efficiency 
or that of the other POC self-tests for monitoring treated CD has not yet been prospectively 
evaluated when this study commenced in 2011. The results of 2 studies published in 2013, 
comparing conventional laboratory results with POC tests other than the one used in our 
study, showed sensitivities of 63% and 84% in treated CD.[26, 27] The false-negative POC 
tests concerned samples with antibody titres near the cut-off of normality.[26, 27] Since 
these low titres are expected in CD patients occasionally making dietary transgressions, this 
group requires a very sensitive POC self-test. The preliminary data of ongoing comparative 
studies using different POC tests to monitor children with treated CD indicate that some 
of them are suitable for this population. The vast majority of our participants favoured the 
POC self-test rather than the conventional venepuncture (80%), implying that these patients 
would welcome the implementation of a properly functioning self-test.
The lack of correlation between TG2A results and self-reported dietary adherence are in 
agreement with those previously reported: in a group of 15 adult CD patients from the Neth-
erlands (9 untreated, 6 making dietary transgressions), only 1 patient had a positive serum 
IgA TG2A.[28] Moreover, serum TG2A was positive in <50% of a group of Italian patients who 
reported dietary transgressions,[27] suggesting that patient interviews are better to evaluate 
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compliance. Nevertheless, a positive serum TG2A is common in patients with self-reported 
‘strict adherence’. They should be referred to a dietician to evaluate their dietary gluten 
content.[6] Moreover, our results show that only a moderate agreement exists between 
the results of the validated questionnaire to assess GFD adherence and the participants’ 
responses to: “I follow a strict gluten free diet”. We did not investigate the reason for this 
discrepancy.
The improvement in CD-specific HRQOL observed after the online consultation, but not 
after the outpatient consultation, is consistent with the previously described positive ef-
fect of SMSs on patients’ coping strategies in relation to their chronic disease.[8, 9] The 
online consultation had a positive effect on the participant’s attitudes towards the GFD 
and communicating their thoughts about their CD. Participant satisfaction with the online 
consultation indicates that the optimal combination of online and outpatient care will be 
different for every patient. In studies with chronically ill adults, age and disease duration 
have been associated with patient activation for e-health.[29, 30] It may be hypothesized 
that in our cohort, young adults who have been diagnosed earlier would use the online 
consultation with ease to manage their disease while those who were recently diagnosed 
(or their parents) would be less enthusiastic. However, these factors were not associated 
with their satisfaction. information about other factors that may have been associated with 
patient motivation for e-health, such as (parental) educational level or place of residence, 
was unavailable in our study.[29, 30]
Medical and non-medical costs of CD follow-up were lower in the online group than in 
the controls. In other chronic diseases, the impact of various SMSs on costs has been 
less conclusive. Some reported positive impacts but others reported increased costs or 
healthcare usage.[8, 31-33] In our study, we found that costs for healthcare usage after 
online consultations were not increased when compared with controls (Table 5). it may 
be argued that the costs of the development and maintenance of the ICT-system for the 
online consultation should have been included in our analysis.[32] However, these costs 
should be distributed over a larger group of users during a longer time period. Moreover, 
our online consultation is not designed to supplement, but substitute, the traditional outpa-
tient consultation. In order to incorporate SMS into the healthcare system for CD patients, 
rendered online services must be reimbursed. In the Netherlands, for example, it is possible 
to register screen-to-screen contact as part of a treatment plan but payment has not yet 
been resolved. By showing that an online consultation is cost-saving, our results suggest a 
return on investment, thereby supporting its reimbursement.
Strengths of our study include its randomized design, comparing an online consultation with 
traditional care in a multicentric setting, including academic and non-academic hospitals. 
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While a previous online intervention successfully targeted increasing the GFD adherence 
and knowledge in Australian CD patients,[34] our study is the first to evaluate an online 
SMS for CD follow-up, taking into account the participant’s physical condition, CD-specific 
HRQOL, dietary adherence and satisfaction, and providing a cost analysis. HRQOL, dietary 
adherence and satisfaction were assessed using validated questionnaires. In addition, we 
did not only consider the expenses incurred by the healthcare sector but also that of the 
participants. National and international guidelines recommend annual testing for anaemia 
and determinations of calcium, folic acid, vitamins D and B12 levels.[1, 6, 35-37] One may 
argue that these parameters were not evaluated in the online consultation. However, 
evidence for the practice of checking such parameters is weak since there is limited infor-
mation on the incidence of nutritional deficiencies in patients with treated CD.[38] Despite 
this finding, some patients (or their parents) refused to participate in the study because 
of the possibility that they (or their child) would be randomized to the group without the 
aforementioned blood tests.
Patients who chose to participate in our study may have had a positive attitude towards 
e-health. This could impact on the generalizability of our results. As we did not inquire 
patients’ reasons for refusal (51%), we remain unaware of their attitude towards e-health. 
On the other hand, comparing our participation (49%) and drop-out rates (8%) with other 
studies evaluating online interventions in chronic diseases (participation rates of 13-42%; 
attrition rates of 12-37%), our study’s recruitment and follow-up were quite successful.[34, 
39-41] Moreover, the lower percentage of drop-outs in the online group than in the controls 
(6% versus 11%) stands in contrast with the findings of a systematic review on e-health inter-
ventions in gastroenterology, showing higher drop-out rates in the intervention group.[42] 
Controls returned for their follow up visits significantly later than online participants, possibly 
because the online group was already familiar with using the POC self-test.
In conclusion, our study showed that online consultations for children and young adults 
with CD are satisfactory and cost-saving instruments that increased CD-specific HRQOL. 
Before implementing online consultations in the follow-up of CD patients, a POC self-test 
that is sensitive enough to detect low positive TG2A levels is required, as these are common 
in patients with treated CD secondary to dietary transgressions. Furthermore, efforts should 
be made to arrange reimbursement of online consultations as part of the treatment plan 
for Cd patients.
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To evaluate and compare three different, commercially available point-of-care (POC) tests 
for anti-tissue transglutaminase (TG2A) in children with treated coeliac disease (CD) against 
results of conventional TG2A at the laboratory using ELISA.
Design
Cross-sectional study, evaluating three different POC tests (X, Y and Z) on 142 blood 
samples from IgA-competent CD patients aged ≤18 years, attending the paediatric gastro-
enterology outpatient clinic of Leiden University Medical Center, the Netherlands. Results 
were evaluated while blinded to the outcome of conventional TG2A assessment (EliAtm 
Celikeytm iga test) at 10 and 30 minutes, and 1 day after performing the test (t10, t30 and 
T1d respectively). We calculated the sensitivity and specificity at 95% confidence intervals 
(CI) and the negative and positive predictive values. A test was considered acceptable if its 
sensitivity was ≥90%.
Results
Serum TG2A was positive in 47/142 samples. Test Y* had a greater sensitivity than the other 
2 evaluated tests (89% [95% CI 0.81-0.98] versus test X: 34% [95% CI 0.20-0.48] and Z: 55% 
[95% CI 0.41-0.70], and its sensitivity was 96% [95% CI 0.90-1.0]) when results were read one 
day after the test was conducted. Prolonging the reading time from T10 to T30 significantly 
improved the performance of tests X and Z in case of positive serum TG2A (sensitivity test 
X 62% [95% CI 0.48-0.76], p<0.001; and test Z 70% [95% CI 0.57-0.83], p=0.016) but for test Z 
this was associated with a drop in specificity.
Conclusions
The studied POC tests have different sensitivities for the relatively low positive TG2A in 
treated CD patients. Prolonging the reading time may improve a test’s performance. To 
implement POC tests in the follow-up of treated CD patients, we recommend the use of 
tests that have been validated in this specific group of patients.
* Celiac quick test for IgA, IgG and IgM TG2A (Biohit Oyj, Helsinki, Finland)
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introduction
Coeliac disease (CD) is a chronic disorder of the small intestine and other organs of ge-
netically susceptible individuals, affecting 1-3% of the Western population.[1] The disease 
is characterized by the production of autoantibodies against a.o. transglutaminase type 2 
(TG2A), among others, during a period of gluten ingestion, which usually disappear 9-12 
months after a gluten free diet (GFD) is initiated.[2-5] Serum detection of TG2A is therefore 
not only useful to screen and diagnose CD but also to monitor a patient’s remission and di-
etary adherence.[6-9] TG2A serum testing is part of standard care in the CD follow-up.[9-12] 
However, TG2A measurement requires specialized laboratories and the results are not im-
mediately available. Readily available TG2A results during consultations with the physician 
would facilitate doctor-patient communication about dietary adherence. Self-testing can 
empower patients in the management of their disease (chapter 4). The call for point-of-care 
(POC) testing, defined as performing a diagnostic procedure outside the laboratory,[13] has 
resulted in the commercial availability of several POC tests for TG2A. These tests obviate 
the need for purified or recombinant transglutaminase type 2 (TG2) or for serum separa-
tion because TG2 is also found in red blood cells (RBCs). Therefore, the patient’s own TG2 
can be used in TG2A detection by haemolysing a whole blood sample and liberating the 
self-TG2 from the RBCs. Tests can be performed at home and results become available 
within 10 minutes, which may save costs and prove to be more convenient for the patients 
(Chapter 4).[14-17] Several studies have investigated the accuracy of POC tests based on 
TG2A for CD screening and diagnosing, and sensitivities and specificities similar to those of 
determination of TG2A in serum were reported (70.1- 97% and 76-100% respectively).[14, 16-
23] There is, however, less consensus over the accuracy of POC testing to monitor CD once 
treatment has been initiated.[20] These patients usually have less TG2A titers than untreated 
patients.[24] Subsequently, the aim of this study was to compare the performance of three 
different, commercially available POC tests against the serum TG2A of CD-affected children 
treated with a Gfd.
metHods
Study design and patients
In this cross-sectional study, we performed 3 different POC tests on IgA-competent CD 
patients aged ≤18 years who attended the paediatric gastroenterology outpatient clinic of 
Leiden University Medical Center (LUMC). The study ran from March 28, 2014 to August 18, 
2015. Patients were included if all inclusioncriteria were met: 1) CD diagnosed according 
to the guidelines of the European Society of Pediatric Gastroenterology Hepatology and 
Nutrition (ESPGHAN); [9] 2) GFD initiated prior to POC testing; and 3) TG2A determined at the 
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hospital laboratory as part of standard care.[12] Information about a patient’s sex, age and 
disease duration was obtained. All identifying details were encoded.
POC tests
POC testing was performed on-site by using 30uL (10uL per POC test) of fresh waste blood 
from a venous whole blood sample that remained in the needle system after venipuncture 
for conventional TG2A determination. The blood was not coagulated or dried. The three POC 
tests that were compared against the conventional TG2A results are henceforth referred to 
as tests X, Y and Z, respectively. Using a lateral flow immunochromatographic strip system, 
the diluted blood sample migrates through the test strip. The principles of the different tests 
vary. For test X, if TG2A are present in the blood sample, they form complexes with the liber-
ated self TG2. These complexes bind to a solid surface protein coated with TG2-capturing 
proteins. A red/pink test line becomes visible with the help of labelled anti-human IgA solu-
tion. in tests y and Z, tG2a (iga, igG for test Z and iga, igG and igm for test y) antibodies in a 
blood sample react with human recombinant TG2 labelled with latex particles. These latex 
particle-TG2-TG2A complexes reach the reaction zone through a chromatographic process, 
where immobilised human TG2 captures the complex, forming a red/pink line. In addition, 
an integrated control system checks proper function of the test by showing a control line. 
A positive test result shows two lines (test and control line), while only one line (the control 
line) appears if the test is negative. A test result with no control line is invalid and cannot 
be used.[25, 26] According to the manufacturers, the test results should be evaluated after 
5-10 minutes. three of this study’s authors, after being trained to assess the PoC tests, 
evaluated and photographed the test results on-site in a well-lit room to determine the 
test result after 10 minutes, but also after 30 minutes and 1 day to assess the stability of the 
test result. Another trained author who was blinded to the outcome of the on-site result 
interpretation and without having any clinical information, evaluated the pictures of the POC 
test results. For assessment of interobserver agreement, the interpretations of the on-site 
and photographed test results were compared.
Conventional serologic testing
The results of IgA TG2A serum testing at the hospital laboratory were used as the gold 
standard. Serum IgA-class TGA were determined with the ELISA technique, using EliAtm 
Celikeytm IgA test (Phadia GmbH, Freiburg, Germany) following the manufacturer’s instruc-
tions. A value of <7 units per milliliter (U/ml) was considered negative while ≥7 U/ml was 
deemed positive. The test has a measuring range of 0.1 - ≥128 U/ml. Results were available 
after approximately 1 week.
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Statistics
For the POC tests, a sensitivity of 90% or higher is considered acceptable. The power cal-
culation is made based on the non-inferiority principle, using test Y. Assuming that the real 
sensitivity of the POC test equals 98% and assuming a required power of 80%, we needed 
to include a minimum of 45 patients who would test positive on the gold standard for TG2A 
determination. In our practice, approximately 35% of the treated CD patients have elevated 
TG2A yearly, including those in their first year after initiating the GFD. This means that the 
expected number of samples which we had to test was estimated to be 129 ((10/3.5)*45) 
Results of each POC test after 10 minutes, 30 minutes and 1 day were used to calculate the 
test’s sensitivity and specificity (with 95% confidence intervals [95% CI]) using two different 
approaches: uninterpretable test results were considered “negative” in the case of a posi-
tive gold standard, and as “positive” in the case of a negative gold standard (“worst case” 
sensitivity and specificity); and when uninterpretable testresults are omitted (“conventional” 
sensitivity and specificity). In the samples with a positive gold standard, the McNemar test 
was used to compare the performance of each POC test when reading time was prolonged 
to 30 minutes or to 1 day, and to compare the performance of the different POC tests’ with 
each other. Inter-observer agreement was evaluated using Cohen’s Kappa (K). Analyses 
were performed with sPss software (version 23.0).
Ethics
The study protocol was approved by the medical ethical committee of the LUMC. No 
informed consent was needed because residual blood was used and TG2A serum de-
termination is standard care. this study is performed according to the standards for the 
reporting of diagnostic accuracy studies (stard). the manufacturers of the PoC tests 
used in this study provided the tests free of charge for the purpose of the study. they were 
neither directly or indirectly involved in the study design or conduct, nor in the analysis of 
the results or preparation of the manuscript.
resuLts
There was a total of 144 blood samples obtained. In 2/144 samples, the amount of blood 
was insufficient to perform all three POC tests. Therefore, 142 blood samples from 122 differ-
ent patients were analysed (testing on 1, 2 or 3 separate occasions during the study period 
in N=104, N=16 and N=2, respectively). Patient characteristics at time of blood withdrawal are 
presented in Table 1. Results of the gold standard for TG2A testing were positive in 47/142 
samples (33%). These belonged to patients with significantly shorter disease duration than 
patients with a sample negative for TG2A (Table 1). the inter-observer agreement between 
interpretation of on-site and photographed POC test results was substantial (0.80, 0.70, and 
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Table 1 characteristics of 122 individual patients with coeliac disease (cd) whose blood samples were with-
drawn and tested for anti-transglutaminase type 2 antibodies (tG2a) with the conventional eLisa in the 
hospital laboratory on 142 occasions, split out for and compared between positive and negative tG2a results 








female gender – n (%) 91 (64.1) 30 (63.8) 61 (64.2) 0.97
age in years – mean (± sd) 9.7 (4.3) 9.8 (4.6) 9.6 (4.1) 0.93
duration of cd in years – mean (± sd) 4.4 (4.2) 1.9 (3.0) 5.7 (4.1) <0.001
serum tG2a titer in u/ml – mean (± sd) 12.5 (24.6) 34.8 (33.1) 1.47 (1.48) <0.001
Figure 1 correlation of the results of iga anti-transglutaminase type 2 (tG2a) in u/ml measured in the labo-
ratory (y-axis) and results of the point-of-care tests ( x-axis) at  10 minutes (t10), 30 minutes (t30) and 1 day 
(T1d) after applying the blood sample. The horizontal dotted line represents the cut-off  for normality of TG2A 
as measured in the laboratory (7 u/ml).
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0.66 for tests X, Y and Z, respectively). The results of the POC tests after 10 minutes (T10), 
30 minutes (T30) and 1 day (T1d) compared with the gold standard are presented in figure 1 
and in Table 2. Uninterpretable test results only occurred in tests Y and Z, and were due to 
the absence of a control line or appearance of a red haze in the test window.
When analysing the results at T10, as recommended by the manufacturer, test X was con-
sidered as false-negative in 31 samples, with serum TG2A titers ranging from 7-128 U/ml 
(mean 27.84 U/ml) (figure 1). Test Y was false-negative in five tests, correlating with TG2A 
levels ranging from 14-23 U/ml (mean 17.40 U/ml) (figure 1). The three uninterpretable tests 
Y concerned samples with negative serum TG2A (figure 1). Test Z was false-negative in 17 
tests, with serum TG2A ranging from 7-60 U/ml (mean 25.47 U/ml) and the 28 uninterpre-
table tests occurred in samples with serum TG2A titers ranging from 0-78 U/ml (mean 5.43 
U/ml). The outcome of all three tests (false negative or true positive) was not influenced by 
time interval since CD diagnosis (p=0.572, 0.323, 0.125 for tests X, Y and Z, respectively) or 
the age of the participant (p=0.492, 0.569, 0.797 for tests X, Y and Z, respectively). In addition, 
the outcome of tests X and Z (false negative or true positive) was uninfluenced by the TG2A 
serum titer (p=0.962 and 0.461 respectively). This in contrast to test Y, where serum TG2A 
levels of tests with a false negative outcome were significantly lower than those of tests 
with a true positive outcome (17.40 U/ml versus 36.80 U/ml, p=0.027). When considering 
the “worst case” scenario (i.e. uninterpretable test results considered “negative” in the case 
of a positive gold standard and as “positive” in the case of a negative gold standard), the 
sensitivities of all 3 tests were less than 90% at T10, with the best outcome for test Y* (89% 
[95% CI 0.81-0.98]) and poorest outcome for test X (34.0% [95% CI 0.20-0.48]) (Table 2).
When confining to those samples with a positive gold standard (N=47), performance of test 
X and Z increased significantly when reading time was prolonged from T10 to T30 (positive 
tests X: N=16 to N=29, p<0.001; positive tests Z: N=26 to N=33, p=0.016) or from T10 to T1d 
(positive tests X: N=16 to N=28, p=0.004; positive tests Z: N=26 to N=31, p=0.031). However, their 
performance at T1d was not significantly improved when compared with T30 (test X p=1.000; 
test Z p=0.500). The improvement in the performance of test Y when reading time was 
prolonged to T30 or T1d, was not statistically significant (p=0.250 and p=0.125 respectively). 
Nevertheless, test Y is the only test whose sensitivity reached a value of over 90% (T30: 91% 
[95% CI 0.84-0.99] and T1d: 96% [95% CI 0.90-1.0]) (Table 2). furthermore, test y performed 
significantly better than X and Z at all evaluated time points in case of positive serum TG2A 
(T10: Y versus X p<0.001, Y versus Z p=0.002; T30: Y versus X p<0.001, Y versus Z p=0.021; T1d: 
Y versus X p<0.001, Y versus Z p=not applicable because all 39 interpretable results of test 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Z were positive with test Y). Test Z performed significantly better than test X at T10 (p=0.007), 
but both tests performed similarly at T30 and T1d (p=0.180 and 0.096, respectively).
discussion
This study evaluated and compared three different commercially available TG2A POC tests 
in children with treated CD against conventional serologic TG2A testing. Our results show 
that test y had a greater sensitivity than the other 2 PoC tests, and that its sensitivity was 
acceptable (95% CI excluded values <90%) if reading time was prolonged from 10 minutes 
to 1 day. Implementation of such a test in a clinical setting may reduce the frequency of 
venipuncture for conventional TG2A testing in children (and probably also in adults) with 
treated CD and could improve self-management of their disease. An important advantage 
of a POC test is its potential to be a more rapid alternative to conventional serologic testing. 
To accommodate the longer reading time of test Y, well instructed patients could do the 
test at home on the day prior to their outpatient clinic visit and bring the test for evaluation 
by their physician. This allows for an on-the-spot management decision in case of a positive 
result. This may include, for instance, conventional serologic testing, dietetic counselling 
on GFD adherence, and discussion with the physician on the harmful effects of gluten 
ingestion. Furthermore, the use of a POC test instead of the conventional TG2A testing may 
have health cost-saving implications, and a finger-prick is considered less invasive than a 
venipuncture, particularly for children (Chapter 4).[27]
Our cohort’s prevalence of positive TG2A in serum (according to conventional serology) 
of 33% is slightly higher than what is reported in literature, with a reported prevalence that 
ranges from 12-32%.[18, 28-32] In contrast to most of these studies, however, we also in-
cluded children diagnosed with CD less than 1 year and therefore with a high likelihood of 
having positive serum TG2A.[5]
A high sensitivity and negative predictive value (NPV) are crucial for monitoring CD activity, 
leading to fewer missed cases of uncontrolled CD. The specificity and positive predictive 
value (PPV) are considered to be less important in this situation, although they do influence 
the efficiency of a POC test. Tests X and Y had been validated in CD screening, with reported 
sensitivities compared to biopsy of 72.2-96.7% for test X,[17, 19, 22, 27] and 77.8% for test Y 
[27]. The lower sensitivities in our study could be explained by the fact that antibody titers in 
treated CD are typically lower than in untreated CD cases identified by screening or case-
finding. However, in a study with 15 patients treated with a strict GFD for 1 year, test X was 
used and compared with the outcome of serum TG2A testing.[19] In 13/15 patients, test X 
was negative, as well as serum TG2A. In the remaining 2 positive tests, serum TG2A values 
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were considered borderline (4.2 and 4.6 U/mL).[19] In addition, in the same study 91 long-
term treated coeliac disease patients (median duration of a strict gluten-free diet = 9 years, 
range 1–24 years) were tested for TG2A with test X and conventional laboratory: 88 (96.7%) 
were negative with test X and 90 (98.9%) with the conventional method.[19] As virtually all 
tests were negative for serum tG2a, this study does not provide enough information about 
the performance of this test in case of low positive serum TG2A. Another study with test X 
suggested that prolonging the reading time to 10-15 minutes increased the sensitivity as 
faint test-lines became clearer.[16] While we also observed this phenomenon in our study, 
it did not result in an acceptable sensitivity for test X. The results of two studies published in 
2013, comparing conventional laboratory results with POC tests other than the ones used in 
our study, showed sensitivities of 63% and 84% in treated CD.[24, 33] The false-negative POC 
tests concerned samples with antibody levels near the cut-off of normality.[24, 33] While 
we also observed this in our study for test Y, tests X and Z yielded false-negative results 
in samples with serum TG2A up to 128 U/ml and 60 U/ml respectively. Based on these 
results, we may conclude that all three tests have different cut-offs of normality. Another 
explanation for their difference in performance may be attributed to the varying principles 
of each of them. Test X uses self-TG2 while tests Y and Z use recombinant human TG2. 
Self-TG2 is known to be a sensitive protein. If the protein is damaged, it may be unable to 
form immunocomplexes with the serum auto-antibodies.[17] It is recommended to avoid 
using blood that has been frozen and thawed multiple times, or blood that is coagulated or 
dried.[17] In our study, however, fresh blood was used on-site and directly from the needle 
system. As the blood was not coagulated or dried, it seemed unlikely that the self-TG2 
was damaged. Furthermore, test X only detects IgA TG2A; while test Z also detects IgG 
TG2A and test Y detects IgA, IgG and IgM TG2A. However, the added value of IgG and 
IgM antibody measurements in our cohort is questionable since all our patients were IgA 
sufficient and all 47 patients with positive conventional ELISA had positive serum TG2A of 
the IgA class. Thus, IgA TG2A was present in all samples that yielded false-negative results.
In a previous study from our hands, evaluating the effectiveness of online consultations 
for follow-up of children and young adults with CD, we found that test X was not sensitive 
enough for home measurements of TG2A in the follow-up of children and young adults with 
treated CD. The results of our present study confirm our previous findings. To the best of our 
knowledge, we are the first to report that prolonging the reading time of test X improves 
its performance in case of positive serum TG2A. A possible explanation could be that the 
haemolysation process, releasing self-TG2 from the erythrocytes, is not completely finished 
after 10 minutes. However, at its peak performance (T30), test X still failed to recognize 
almost 40% of the positive samples, indicating that prolonging the reading time from 10 to 
30 minutes or 1 day will not make the test suitable for utilization in patients with treated CD. 
For test Z, we do not recommend prolonging reading time to 30 minutes or 1 day due to 
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the associated significant drop in specificity. Furthermore, test Z showed a high number of 
uninterpretable test results (N=28 after 10 minutes) caused by the absence of a control line 
in 27 of them. as these tests’ expiration dates have not yet passed and this event occurred 
in tests that were all from the same batch, this was almost certainly a manufacturing defect. 
Nevertheless, when these uninterpretable results were disregarded, the sensitivity of test Z 
at T10 was still unacceptable for follow-up of treated CD (conventional sensitivity 0.60; 95% 
Ci 0.46-0.75).
The strengths of our study include a design wherein the same trained personnel carried 
out three different commercially available POC tests on the same blood sample and evalu-
ated the outcome, blinded to the results of the conventional ELISA that was performed in 
the same laboratory throughout the study. Additionally, we used the widely implemented 
EliAtm Celikeytm IgA test (Phadia GmbH, Freiburg, Germany) as the gold standard to mea-
sure serum TG2A, thereby increasing the generalizability of our results. To the best of our 
knowledge, we are the first to report the results of three different commercially available 
POC tests in monitoring treated CD. One may argue that we should have included adher-
ence to the GFD as a variable in our analysis. However, as an objective tool to assess dietary 
adherence is not available, serum TG2A and dietary adherence do not always agree.[24, 34] 
Furthermore, it may be argued that we assessed inter-observer variability by comparing 
the on-the-spot evaluation with the interpretation of a photograph of the result. While the 
agreement between these methods was acceptable for all three tests, the positive tests 
with a faint test line were difficult to capture on a photograph. However, our results sug-
gest that photographs of POC test results have the potential to be used as an alternative 
for on the spot evaluation of the results. This could be useful in self-management pro-
grammes, wherein CD patients could send a photograph of the test result to their physician. 
Alternatively, a reader could be developed that will interpret the photographed test result, 
minimizing the risk of observer bias.
In conclusion, we found that out of the 3 studied POC tests for TG2A, the Celiac Quick Test 
for IgA, IgG and IgM TG2A (Biohit Oyj, Helsinki, Finland) had the highest sensitivity for TG2A 
in children with treated CD. We recommend reading this test’s results a day after performing 
it and that further validation studies be carried out in patients with treated CD.
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General disCUssion and ConClUsion
Parts of this chapter have been published as
vriezinga sL, moll Ha, mearin mL
is it time for mass screening for celiac disease?





Coeliac disease is a common condition with a variable presentation, and is frequently not 
recognized by physicians. Although a gluten-free diet has a positive effect on the health of 
the coeliac patient, prevention would be even more beneficial. Accordingly, the first aim of 
this thesis was to investigate the influence of infant feeding on the prevention and develop-
ment of childhood coeliac disease.
Primary prevention of coeliac disease means that tolerance for gluten needs to be 
achieved or maintained. As mentioned in the introduction of this thesis, results from previ-
ous retrospective studies suggested that the introduction of gluten between the age of 4 
months and 6 months represents a window of opportunity for preventing coeliac disease.[1, 
2] Based on these results both Dutch and European guidelines recommended introducing 
gluten not before the age of 17 weeks and not after the age of 26 weeks, preferably during a 
period of breastfeeding. However, the results of the PreventCD study, which are presented 
in chapter 2, did not show the hypothesized benefit of early exposure to small quantities of 
gluten with regard to reducing the incidence of coeliac disease among children from high 
risk families. In addition, maintenance of breastfeeding at the time of gluten introduction, 
and breastfeeding in general, did not reduce the risk of this disorder. Although we want to 
underscore the overall importance of breastfeeding for child health, our results may allevi-
ate the stress that is placed on mothers, especially those from coeliac families, who are 
unable to breastfeed their baby: it will not increase their baby’s risk for coeliac disease.
Our results are in agreement with those of other recent prospective studies (CELIPREV, 
Generation R, MoBa, and TEDDY).[3-6] CELIPREV is a prospective multicenter intervention 
study with Italian children who have a familial risk for coeliac disease, followed from birth 
and randomized to gluten introduction at the age of 6 months or 12 months.[5] Delaying 
gluten introduction and breastfeeding did not modify the risk of coeliac disease, although 
gluten introduction at 12 months was associated with a delay in disease onset. The HLA 
genotype was an important predictor of disease. Furthermore, the results of the Dutch 
‘GenerationR Study’, a Rotterdam population-based prospective cohort study from foetal 
life until young adulthood, showed that the risk of coeliac disease autoimmunity is not influ-
enced by introducing gluten after the age of 6 months, or by breastfeeding during the first 
6 months of life.[4] The Norwegian Mother and Child Cohort Study (MoBa) is a prospective 
population-based pregnancy cohort study, conducted by the Norwegian Institute of Public 
Health.[6] Introducing gluten after the age of 6 months and breastfeeding past the age of 
1 year were associated with a modest increase in the clinical diagnosis of coeliac disease. 
Gluten introduction during the period of breastfeeding was not protective. The Environmen-
tal Determinants of Diabetes in the Young (TEDDY) is a multinational study with children at 
high risk for type 1 diabetes and a genetic predisposition of coeliac disease (HLA-DQ2/
DQ8).[3] Gluten introduction before the age of 17 weeks or after the age of 26 weeks was 
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not associated with an increased risk of coeliac disease. Finally, a systematic review that 
included the aforementioned prospective studies concluded that breastfeeding and timing 
of gluten introduction have no effect on the risk of developing coeliac disease during child-
hood, necessitating for an update of the current European guidelines.[7] These guidelines 
were been prepared by the European Society for Paediatric Gastroenterology Hepatology 
and Nutrition (ESPGHAN) in collaboration with the PreventCD group, and recommend 
that gluten can be introduced into the infant’s diet between the ages of 4 and 12 months, 
but state that the age of gluten introduction in infants in this age range does not seem to 
influence the absolute risk of developing coeliac disease during childhood.[8] Furthermore, 
according to the guideline, introducing gluten while the infant is being breastfed cannot be 
recommended as a means of reducing the risk of developing coeliac disease.[8]
While prevention of coeliac disease is not possible at this moment, diagnosing the disease 
in its earliest stage – secondary prevention – may be a realistic alternative. One way to pur-
sue this is by case-finding: actively seeking for symptoms associated with coeliac disease 
(see box 1 in chapter 1) and a low threshold use of further examinations. Because of the 
variable presentation of coeliac disease, this will not resolve its underdiagnosis. Therefore, 
the current evidence-based guidelines recommend screening for coeliac disease in 
high-risk groups (see box 2 in chapter 1). This screening involves determination of coeliac 
disease specific antibodies against tissue transglutaminase (TG2A) or endomysium (EMA) in 
serum.[9] As presented in chapter 2, TG2A are reliable predictors of coeliac disease, also in 
very young children.[10] First-degree relatives of coeliac patients have an elevated risk for 
coeliac disease of 2-20%, depending on sex and HLA-genotype.[10] Furthermore, coeliac 
disease appears at a very young age (<3 years old) in children with a first-degree relative 
with coeliac disease: In children diagnosed with coeliac disease and a positive family his-
tory, 50% had developed the disease by age 3 years, implying that one should start with 
screening prior to this age.[10] In addition, coeliac disease has a female preponderance 
of 2-3:1 by 3 years of age, with in an incidence of 7.2% in girls with a positive family history 
versus 3.4% in boys.[10] Children homozygous for HLA-DQ2 clearly have a higher risk of 
coeliac disease (14.9%) than HLA-DQ2 heterozygous (3.9%) and HLA-DQ8 positive (hetero- 
and homozygous) children (0.9%), (p<0.001).[10]
Would mass screening for coeliac disease be a sensible alternative to case-finding? Ten 
years ago, when Wilson and Junger’s criteria for mass screening were applied to coeliac 
disease, there was controversy over whether the general population would accept mass 
screening and whether the health status of minimally symptomatic or asymptomatic 
patients identified by mass screening improved after treatment.[11, 12] Furthermore, the 
natural course of the disease and cost-effectiveness of mass screening were unclear.[11, 




ish ETICS-PreventCD study has shown that mass screening for coeliac disease in 13.279 
children aged 12-year old was feasible and well-accepted.[1] Results from the ‘GenerationR 
Study’ among 6-year old children from the general population provided information about 
the natural course of coeliac disease. Undiagnosed coeliac disease was found in 1.3% 
(57/4442 screened children was positive for TG2A) and was associated with important health 
problems, such as a reduced bone mineral density and a delayed growth in weight.[13] In 
addition, children of women with undiagnosed and thus untreated coeliac disease had a 
reduced fetal growth and a lower birth weight.[14] Concerning the costs of mass screening, 
the results of a study concerning coeliac disease screening in adults showed that screening 
has a cost-effectiveness ratio of 48.960 USD per QALY. Based on this outcome, the authors 
suggest that mass screening for coeliac disease is indeed cost-effective.[15] Confirming the 
diagnosis in asymptomatic patients still requires obtaining small bowel biopsies according 
to the current evidence-based guideline of the ESPGHAN.[9] This in contrast to patients with 
coeliac disease associated symptoms, TG2A titres of more than 10 times the upper limit of 
normal, a positive EMA in a new blood sample and HLA-DQ2/DQ8 positivity. Results from 
the Swedish ETICS screening study show that this also applies to children diagnosed after 
screening.[16] The prospective and international PRoCeDe study will provide information 
about this as well.[17] It would make the process of diagnosing coeliac disease in children 
identified by screening simpler, less invasive and cheaper. An argument that is frequently 
used against mass screening is that minimally symptomatic or asymptomatic patients will 
not adhere to the gluten free diet. However, long-term follow-up of young Dutch children 
and the results of the study with 12-year old Swedish children disprove this argument: the 
children were compliant with their diet.[18, 19] Furthermore, a prospective study showed 
that treatment of coeliac disease diagnosed based on mass screening yields health gains, 
both for adults and children.[18] In Dutch children with coeliac disease identified by mass 
screening, chronic symptoms of diarrhoea, abdominal pain, constipation, fatigue, irritability, 
oral aphthous ulcers and growth failure, improved after diagnosis and treatment.[18] In adult 
Finnish coeliac patients who were diagnosed after screening, chronic health problems as 
indigestion, gastro-oesophageal reflux and anxiety improved significantly after treatment 
with a gluten-free diet.[20] Furthermore, dietary adherence was excellent after screening 
and there were no significant differences between screening-detected and symptom-
detected patients with regard to coeliac disease-health related quality of life.[18, 20, 21] 
Consequently, secondary prevention may only be achieved on large scale by mass screen-
ing of the general population.
Traditional medical care for patients with treated coeliac disease consists of regular physi-
cian visits to evaluate their health, weight, height (in children), gluten-free diet adherence 
and coeliac-specific serum antibodies.[22, 23] Although important, these measures can be 
time-consuming. Moreover, many patients do not visit their physician for regular follow-
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up.[24] Time constraints during outpatient follow-up also typically restrict comprehensive 
assessments of a patient’s health-related quality of life (HRQOL) and dietary adherence. 
Accordingly, the second aim of this thesis was to explore new strategies for the improve-
ment of care for children and young adults with coeliac disease.
While coeliac disease-specific HRQOL is an accepted outcome within a research envi-
ronment, insufficient time during actual follow-up visits may prevent the physician from 
specifically measuring it, and therefore only general assessments can be provided. It has 
been established that in patients with other chronic diseases, the physician overestimates 
the patient’s HRQOL [25-27]. We are the first to have compared the self-reported coeliac 
disease-specific HRQOL in a group of children and young adults with the physician’s report 
provided during a regular outpatient follow-up visit for coeliac disease (chapter 3). our 
results indicate that there is an important discrepancy between these reports since in 57% 
of the patients, the physician had a different perception of the patients’ HRQOL than the 
patient him/herself. What raises concern is that this occurred among patients considered 
to be especially vulnerable: those with a “bad” self-reported HRQOL. Our data show that 
this problem occurs significantly more frequently in those who received the diagnosis 
within the past 9 years and in female patients, possibly due to their significantly poorer 
self-reported HRQOL, especially for the “communication” subscale, compared to their male 
counterparts (p=0.014). Our results concerning the discrepancy between the self-reported 
and physician-reported HRQOL are consistent with previous studies with children affected 
by other chronic diseases [25-27]. Our study supports the implementation of a self-reported 
coeliac disease-specific HRQOL measurement in the clinical follow-up of the patients. 
Sharing the results of the questionnaire may improve the patient/parent-doctor communi-
cation and the physicians’ understanding of the needs and priorities of children and young 
adults with coeliac disease. As the standard consultation time allotted for follow-up visits 
is limited, the outpatient clinic of the department of paediatric gastroenterology of Leiden 
University Medical Centre will ask the patient to complete the CDDUX questionnaire prior to 
physician appointments. If our results are successful, we will advise other hospitals caring 
for patients with coeliac disease to follow-up on our example.
Previous studies in adults with other chronic diseases suggest that an online self-manage-
ment e-health system can encourage patients to improve health care participation and 
the decision-making process.[28] Patients are able to deal with their symptoms, treatment, 
physical and psychosocial consequences and lifestyle changes that are inherent in living 
with a chronic condition through successful disease self-management.[29] In chapter 4, 
we presented the results of an online consultation replacing outpatient consultations in the 
follow-up of coeliac children and young adults (CoelKids). We hypothesized that disease 




and traditional outpatient follow-up. To the best of our knowledge, this is the first study 
investigating a self-management intervention in this specific population on a physical, psy-
chological, nutritional and economic level. Our results indicate that the online consultation 
for children and young adults with coeliac disease is an effective and satisfactory instrument 
for self-management of their disease. Symptoms were recognized significantly more often 
in the online than the outpatient consultations, possibly because the online consultation 
initiated a conversation about symptoms between parent and child that was not restricted 
by the limited time available for an outpatient consultation. Abnormal growth was similarly 
recognized through both approaches. Additionally, online consultations increased the co-
eliac disease-specific HRQOL while its mean costs were lower compared with the costs of 
traditional care. Results from the POC self-test for TG2A assessment showed the used test 
is unfit for the population under study. The used self-test has been validated for coeliac dis-
ease screening, with reported sensitivities and specificities of ≥94% and ≥93%, respectively.
[30, 31] However, its efficiency or that of the other POC self-tests for monitoring treated 
coeliac disease had not yet been prospectively evaluated when this study commenced in 
2011. These patients usually have less high titers of TG2A than untreated patients.[32] Before 
implementing online consultations in the follow-up of coeliac patients, a POC self-test that 
is sensitive enough to detect low positive TG2A levels is required, as these are common in 
patients with treated Cd secondary to dietary transgressions.
Triggered by the inadequate performance of the POC self-test used in the CoelKids study 
(chapter 4), we compared the performance of three commercially available POC tests 
against the serum TG2A of coeliac disease-affected children treated with a gluten free diet 
(chapter 5). Our results show that the sensitivity of one of these three tests was acceptable 
(95% confidence interval excluded values <90%) if the reading time was prolonged from 10 
minutes to 1 day. For all three POC tests, we find lower sensitivities than previous studies 
using these tests in screening for coeliac disease. This could be explained by the fact that 
antibody titres in treated CD are typically lower than in untreated CD cases identified by 
screening or case-finding. Another explanation for their difference in performance may be 
attributed to the varying principles of each of them; one only tests for IgA TG2A, one for IgA 
and IgG TG2A and the other for IgA, IgG and IgM TG2A. However, the added value of IgG 
and IgM antibody measurement in our cohort is questionable since IgA TG2A was present 
in all samples that yielded false-negative results. Implementation of a POC test for TG2A in 
a clinical setting may reduce the frequency of venepuncture for conventional TG2A testing 
in children (and probably also in adults) with treated coeliac disease and could improve 
self-management of their disease. An important advantage of a POC test is the potential 
of being a more rapid alternative to conventional serologic testing. To accommodate the 
longer reading time that is required to obtain an acceptable sensitivity, well instructed pa-
tients could do the test at home on the day prior to their outpatient clinic visit and bring the 
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test for evaluation by their physician. This allows for an on-the-spot management decision 
in case of a positive result, for example: conventional serologic testing, dietetic counselling 
regarding the adherence to the gluten free diet and discussion with the physician on the 
harmful effects of gluten ingestion. Furthermore, as shown in chapter 4, the use of a PoC 
test instead of conventional TG2A testing may have health cost-saving implications, [33] 
and a finger prick is experienced to be less invasive than a venepuncture, particularly for 
children. For implementation of POC tests in the follow-up of treated coeliac patients we 
recommend to use tests that have been validated in this specific group of patients. To rule 
out the risk of observer variability, a ‘reader’ that automatically interprets the result of the 
POC self-test should be developed and prospectively tested in the follow-up of patients 
with treated coeliac disease. This could, for example, be a smartphone application that 
interprets a photograph of the test result.
In conclusion, new developments with respect to prevention and management of coeliac 
disease are taking place at a fast pace. The results presented in this thesis have altered 
the conceptual landscape of coeliac disease[34] and increased our understanding of the 
risk factors associated with this disease (chapter 2). Furthermore, they call for an update of 
the current national and international guidelines on infant feeding. A recommendation for 
improvement of patient/parent-doctor communication on patients’ HRQOL is presented 
in chapter 3 and a self-management e-health system for coeliac patients is evaluated in 
chapter 4. Finally, we presented a POC test that may be suitable for follow-up of treated 
coeliac disease in chapter 5.
Future perspectives
The lack of an association between the timing of gluten introduction, the duration and pres-
ence of breastfeeding, and the development of coeliac disease keeps us guessing for an 
explanation for the striking increased incidence of this disease in the Western world during 
the recent decades. It remains likely that other environmental factors play an important 
role, such as the gut microbiome. It has been suggested that intestinal dysbiosis is as-
sociated with coeliac disease.[35] It is however unknown whether the alterations are cause 
or consequence of the disease. To answer questions such as “Who will develop coeliac 
disease?” and “When will this happen?” it is crucial to prospectively collect and study the 
blood, faeces and duodenal biopsies (‘biobanking’) from patients at high-risk for developing 
coeliac disease (see the appendix for a letter to the medical ethical committee of the Leiden 
University Medical Centre concerning biobanking). In a subproject of the PreventCD study, 
we plan to annually collect faeces of the participating children to establish the relationship 




Is it time to start with mass screening for coeliac disease instead of only screening people 
from coeliac families? Perhaps we are nearly there, but a couple of questions remain un-
answered. Such as: what is the optimal screening method and frequency and at what age 
should we screen? It also needs to be clarified whether the costs of screening and treat-
ment are acceptable when compared with the total costs of healthcare. Recent advances 
in the diagnostics of coeliac disease, such as the POC tests for TG2A, will lower the costs 
of mass screening and will increase cost-effectiveness. Future studies should take these 
features into account but also focus on the ethical aspects of mass screening with the 
different available diagnostic tools in different age categories.
In the coming years, e-health is envisaged to play an increasing role in the care for patients 
with a chronic disease. this thesis (chapters 4 and 5) showed that also in treated coeliac 
disease, an online consultation is a satisfactory alternative for an outpatient follow-up visit. 
Before implementing online consultations in these patients’ health care, it is necessary to 
validate the POC self-test for TG2A in this specific population. Recently, a new option for the 
assessment of gluten free diet adherence has been described: detection of gluten immu-
nogenic peptides in urine.[36] This may be a less invasive, cheaper and possibly even more 
reliable alternative to conventional blood testing or POC testing for TG2A. However, stud-
ies that validate the relevance of this method in clinical practice are required. To maintain 
participant engagement with e-health, we suggest adjusting to the increased popularity 
of medical applications on smartphones and tablets. Furthermore, efforts should be made 
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This thesis aims to investigate the influence of infant feeding on the development and 
primary prevention of childhood coeliac disease. It explores new strategies for the improve-
ment of care for children and young adults with this disorder.
Chapter 1 provides a general introduction and an overview of the literature on the patho-
genesis, diagnosis, management and primary prevention of childhood coeliac disease.
Chapter 2 presents the results of a multicentre, randomized, double-blind placebo con-
trolled dietary intervention study involving 944 children, all positive for HLA-DQ2 and/or 
HLA-DQ8 and with at least one first-degree relative with coeliac disease. During 16 to 24 
weeks of age, participating children received 100 mg of immunologically active gluten 
per day, or placebo. Anti-transglutaminase type 2 (TG2A) and antigliadin antibodies were 
measured regularly. When all children had reached the age of 3 years, 80 children were 
diagnosed with coeliac disease. The median age at diagnosis was 2.8 years and 59% were 
girls. The cumulative incidence of coeliac disease among 3-year-old children was 5.2% (95% 
confidence interval [CI], 3.6-6.8), with similar rates in the gluten group and the placebo group 
(5.9% [95% CI, 3.7-8.1] and 4.5% [95% CI, 2.5-6.5], respectively). The hazard ratio in the gluten 
group was 1.23 (95% CI, 0.79-1.91). Breastfeeding, regardless of whether it was exclusive or 
whether it was ongoing during gluten introduction, did not significantly influence the devel-
opment of coeliac disease or the effect of the intervention. In conclusion, the introduction 
of small quantities of gluten at 16 to 24 weeks of age, as compared with placebo, did not 
reduce the risk of coeliac disease by 3 years of age in this group of high-risk children. The 
present European guidelines recommend introducing small amounts of gluten gradually 
while the child is breastfed and avoiding both early (<4 months) or late (>7months) introduc-
tion of gluten. Our results have contributed to the development of new European guidelines 
for the introduction of gluten in the diet of young children.
Chapter 3 reports the results of a cross-sectional study investigating whether implementa-
tion of a coeliac disease-specific health related quality of life (HRQOL) questionnaire would 
add value to the follow-up visits for coeliac disease; we compared patients’ self-reported 
coeliac disease-specific HRQOL with the physician’s report provided during a regular 
follow-up visit for coeliac disease in children and young adults. Eligible patients were diag-
nosed with coeliac disease for at least 1 year, and were up to 25 years old. They completed 
a coeliac disease-specific HRQOL questionnaire, the CDDUX, after their regular follow-up 
visit for coeliac disease. Their physicians were unaware of the current study’s objectives or 
the self-reported HRQOL. Physician-reported HRQOL was available in 70/78 enrolled pa-
tients. The self-reported and physician-reported HRQOL were concordant in 30/70 cases 
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(κ=0.093), 6 of these patients had a poor self-reported HRQOL. The reports were discrep-
ant in 40/70 cases, all 40 patients reported a poor HRQOL. We found that discrepancies 
occurred more frequently in patients with a disease duration shorter than 9 years (32/40 
children with discrepant assessments were diagnosed <9 years ago versus 17/30 with no 
discrepancy, p<0.001) and in females (35/40 children with discrepant assessments were 
girls versus 16/30 with no discrepancy, p=0.001). Both factors were predictors of a poorer 
HRQOL. In conclusion, we found that during regular follow-up visits for coeliac disease, 
physicians did not report a poor HRQOL in 40/46 children and young adults with a poor 
self-reported HRQOL. This is consistent with previous studies examining other chronic dis-
eases and supports the implementation of self-reported coeliac disease-specific HRQOL 
measurements in follow-up visits of coeliac patients.
the objective of the study presented in chapter 4 was to evaluate the effectiveness of 
online consultations for follow-up of children and young adults with coeliac disease. They 
were included in the CoelKids study, a multicentre randomized controlled trial involving 
patients diagnosed with coeliac disease for at least 1 year and aged up to 25 years old. They 
received an online consultation or a traditional outpatient consultation. Online consulta-
tions included symptom questionnaires and home measurements of growth and TG2A 
using a point-of-care (POC) self-test. Both groups completed questionnaires concerning 
coeliac disease-specific HRQOL, gluten free diet adherence and patient-satisfaction. After 
6 months, they performed the POC self-test and repeated HRQOL and patient-satisfaction 
questionnaires. We found that with the online consultation, abdominal pain, lassitude and 
increased appetite were detected significantly more frequently than in controls with the 
traditional consultation. Growth problems were detected similarly in both groups. TG2A was 
positive in 2 online participants and 13 controls (POC versus laboratory, p=0.003). CD-specific 
HRQOL (1=good; 5=poor) was similar in both groups, but improved after online consulta-
tion (3.25 to 3.16, p=0.013; versus controls 3.10 to 3.23, p=0.810). Patient-satisfaction (1=low; 
10=high) was 7.6 in the online group and 8.0 in controls (p=0.001). Mean costs per participant 
of the online group were €202 less than in the control group (p<0.001). In conclusion, we 
found that online consultations for children and young adults with coeliac disease are cost-
saving and increase coeliac disease-specific HRQOL. Additionally, patients find these to 
be satisfactory. The discrepancy between the POC test and laboratory results suggests 
that the used POC test is not sensitive enough to detect low antibody levels and thereby 
unsuitable to monitor treated coeliac disease.
Chapter 5 present the result of a cross-sectional study evaluating and comparing 3 different 
commercially available POC tests for TG2A in children with treated coeliac disease against 
results of conventional TG2A at the laboratory with ELISA. Tests X, Y and Z were performed 




the paediatric gastroenterology outpatient clinic of Leiden University Medical Center, the 
Netherlands. Results were evaluated blinded to the outcome of conventional TG2A assess-
ment (EliAtm Celikeytm iga test) 10 and 30 minutes and 1 day after performing the test (t10, 
T30 and T1d respectively). Performance of tests was acceptable if the sensitivity was ≥90%. 
The serum TG2A was positive in 47/142 samples. Test Y had a greater sensitivity than the 
other 2 evaluated tests (89% [95% CI 0.81-0.98] versus test X: 34% [95% CI 0.20-0.48] and Z: 
55% [95% CI 0.41-0.70]), and its sensitivity was 96% [95% CI 0.90-1.0]) when results were read 
1 day after the test was carried out. Prolonging the reading time from T10 to T30 significantly 
improved the performance of tests X and Z in case of positive serum TG2A (sensitivity test 
X 62% [95% CI 0.48-0.76], p<0.001; and test Z 70% [95% CI 0.57-0.83], p=0.016) but for test 
Z this was associated with a drop in specificity. In conclusion, our results showed that the 
studied POC tests have different sensitivities for the relatively low positive TG2A in treated 
coeliac disease patients. Performance of these tests may improve when reading time is 
prolonged. Before implementing POC tests in the follow-up of treated coeliac patients, we 
recommend to use tests that have been validated in this specific group of patients.
Chapter 6 contains the general discussion and the conclusion of this thesis. We set out 







Dit proefschrift heeft als doel het onderzoeken van de invloed van vroege voeding op de 
primaire preventie en ontwikkeling van coeliakie. Daarnaast richt het zich op nieuwe strate-
gieën voor verbetering van zorg voor kinderen en jong volwassenen met deze aandoening.
Hoofdstuk 1 geeft een overzicht van de huidige literatuur over de pathogenese, diagnose, 
behandeling en primaire preventie van coeliakie.
Hoofdstuk 2 beschrijft de resultaten van een multi-centrum, gerandomiseerde, dubbel-
blinde placebogecontroleerde voedings-interventie studie. Alle 944 deelnemende kinde-
ren zijn positief voor HLA-DQ2 en/of HLA-DQ8 en hebben ten minste één eerstegraads 
familielid met coeliakie. Deelnemers kregen gedurende de leeftijd van 16 tot en met 24 
weken dagelijks 100 mg immunologisch actief gluten, of placebo. Hun bloed werd regel-
matig onderzocht op anti-transglutaminase type 2 (TG2A) en antigliadine antilichamen. 
Toen alle kinderen drie jaar oud waren, was bij 80 kinderen de diagnose coeliakie gesteld. 
De mediane leeftijd waarop dit gebeurde was 2.8 jaar, meisjes waren in de meerderheid 
(59%). Op de leeftijd van drie jaar was de cumulatieve incidentie van coeliakie 5.2% (95% be-
trouwbaarheidsinterval [BI], 3.6-6.8), met gelijke frequenties in de gluten en placebo groep 
(respectievelijk 5.9% [95% BI, 3.7-8.1] en 4.5% [95% BI, 2.5-6.5]). De hazard ratio in de gluten 
groep was 1.23 (95% BI, 0.79-1.91). Hoe lang borstvoeding werd gegeven, en of borstvoeding 
nog werd gegeven toen gluten werden geïntroduceerd, had geen invloed op het risico op 
coeliakie en ook niet op het effect van de gluten-interventie. Samenvattend: in vergelijking 
met placebo had de introductie van kleine hoeveelheden gluten gedurende de leeftijd van 
16 tot en met 24 weken geen effect op het risico op coeliakie bij drie jaar oude kinderen uit 
hoog-risico gezinnen. De huidige Europese richtlijnen adviseren om kleine hoeveelheden 
gluten geleidelijk te introduceren terwijl het kind nog borstvoeding krijgt. Daarnaast advi-
seren zij om gluten niet voor de leeftijd van vier maanden en niet na de leeftijd van zeven 
maanden te introduceren. Onze resultaten hebben bijgedragen aan de ontwikkeling van 
nieuwe Europese richtlijnen voor de introductie van gluten in het dieet van jonge kinderen.
Hoofdstuk 3 rapporteert de resultaten van een onderzoek naar de toegevoegde waarde van 
het gebruiken van een vragenlijst over de coeliakie-specifieke gezondheids-gerelateerde 
kwaliteit van leven bij het volgen van kinderen en jongvolwassenen met coeliakie. Daarvoor 
hebben wij een vergelijking gemaakt tussen de coeliakie-specifieke gezondheids-gerela-
teerde kwaliteit van leven zoals de patiënt het zelf rapporteert met behulp van een vragen-
lijst, en zoals de arts het rapporteert tijdens een standaard vervolgconsult voor coeliakie. 
Patiënten kwamen in aanmerking voor de studie als zij ten minste 1 jaar coeliakie hadden en 
maximaal 25 jaar oud waren. Na hun standaard vervolgconsult voor coeliakie vulden ze een 
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coeliakie-specifieke gezondheids-gerelateerde kwaliteit van leven vragenlijst in, de CD-
DUX. De deelnemende artsen waren niet op de hoogte van het doel van deze studie, noch 
van de uitkomst van de vragenlijst. Uit het patiëntendossier van 70/78 deelnemers kon de 
kwaliteit van leven van de patiënt zoals beoordeeld door de arts worden geëxtraheerd. De 
zelf-gerapporteerde en arts-gerapporteerde kwaliteit van leven kwam overeen in 30/70 
patiënten (K=0.093), 6 van deze patiënten had een lage zelf-gerapporteerde kwaliteit van 
leven. In 40/70 deelnemers kwamen de metingen niet overeen, alle 40 patiënten rap-
porteerden een lage kwaliteit van leven. Deze discrepantie kwam vaker voor bij patiënten 
met een ziekteduur korter dan 9 jaar (32/40 patiënten met niet-overeenkomende metingen 
waren minder dan 9 jaar geleden gediagnosticeerd, versus 17/30 met wel-overeenko-
mende metingen, p<0.001), en in vrouwen (35/40 deelnemers met niet-overeenkomende 
metingen waren vrouwelijk, versus 16/30 met wel-overeenkomende metingen, p=0.001). 
Beide factoren waren indicatief voor een lage zelf-gerapporteerde kwaliteit van leven. In 
de conclusie wordt tijdens een standaard vervolgconsult voor coeliakie een lage coeliakie-
specifieke gezondheids-gerelateerde kwaliteit van leven gemist bij 40/46 kinderen en 
jong volwassenen. Dit komt overeen met eerdere studies naar andere chronische ziekten 
en ondersteunt de implementatie van een vragenlijst voor het meten van de coeliakie-
specifieke gezondheids-gerelateerde kwaliteit van leven tijdens (of voorafgaande aan) een 
vervolgconsult voor coeliakie.
Het doel van de studie in hoofdstuk 4 is het evalueren van de effectiviteit van een online 
consult als vervanging van een vervolgconsult voor kinderen en jongvolwassenen met 
coeliakie. Zij doen mee aan de CoelKids studie, een multicentrum en gerandomiseerde 
studie met coeliakiepatiënten die ten minste 1 jaar geleden gediagnosticeerd zijn en 
maximaal 25 jaar oud zijn. Ze werden gerandomiseerd naar de online groep of de controle 
groep. De online groep voltooide een online consult, de controle groep een traditioneel po-
liklinisch consult. Tijdens het online consult werden symptomen uitgelicht aan de hand van 
een vragenlijst en werd TG2A thuis gemeten met behulp van een point-of-care (POC) test. 
Beide groepen vulden vragenlijsten in over coeliakie-specifieke gezondheid-gerelateerde 
kwaliteit van leven, het volgen van het glutenvrij dieet en patiënttevredenheid. Na 6 maan-
den deden alle deelnemers de POC test en herhaalden ze de vragenlijsten over kwaliteit 
van leven en patiënttevredenheid. De online groep gaf, vaker dan de controle groep, aan 
last te hebben van buikpijn, moeheid en een toegenomen eetlust. Groeiproblemen werden 
in beide groepen even vaak gevonden. TG2A was positief in 2 online deelnemers en in 
13 controles (POC versus standaard laboratorium test, p=0.003). De coeliakie-specifieke 
kwaliteit van leven (1=hoog, 5=laag) was gelijk in beide groepen, maar nam 6 maanden na 
een online consult significant toe (3.25 naar 3.16, p=0.013; versus controlegroep 3.10 naar 
3.23, p=0.810). Patiënttevredenheid (1=laag; 10=hoog) was 7.6 in de onlinegroep en 8.0 in 




€202 lager dan in de poligroep (p<0.001). Wij concluderen dat een online consult voor kin-
deren en jong volwassenen met coeliakie kostenbesparend is en de coeliakie-specifieke 
gezondheids-gerelateerde kwaliteit van leven verhoogt. Tevens blijken patiënten tevreden 
over het online consult. De discrepantie tussen de uitslagen van de POC en laboratorium 
testen suggereert dat de gebruikte POC test niet sensitief genoeg is om laag-verhoogd 
TG2A aan te tonen en is daarmee ongeschikt voor het volgen van patiënten met behan-
delde coeliakie.
Hoofdstuk 5 presenteert de resultaten van een studie waarin 3 verschillende commercieel 
beschikbare POC testen (test X, Y en Z) voor TG2A worden toegepast in de follow-up van 
kinderen met behandelde coeliakie. De uitslagen van de testen werden onderling verge-
leken, en met de ‘gouden standaard’: de uitslag van conventionele TG2A bepaling in het 
laboratorium met ELISA (EliAtm Celikeytm iga test). deze drie testen werden uitgevoerd op 
142 bloedsamples van IgA competente kinderen met behandelde coeliakie (maximaal 18 
jaar oud), die de polikliniek van het Leids Universitair Medisch Centrum bezochten voor 
follow-up van hun ziekte. De uitslag van de POC test werd geëvalueerd na 10 en 30 mi-
nuten, en na 1 dag (T10, T30 en T1d). De uitslag van de conventionele ELISA bepaling was 
toen nog niet bekend. De POC test werd geschikt bevonden als de sensitiviteit ≥90% was. 
Volgens de conventionele ELISA was het serum TG2A positief in 47/142 bloedsamples. De 
sensitiviteit van test Y was groter dan van de andere 2 testen (89% [95% BI 0.81-0.98] versus 
test X: 34% [95% BI 0.20-0.48] en Z: 55% [95% BI 0.41-0.70]). Op T1d was de sensitiviteit van 
test Y 96% [95% BI 0.90-1.0]. Voor testen X en Z was het significant gunstiger om de uitslag 
op T30 in plaats van T10 af te lezen (sensitiviteit test X 62% [95% BI 0.48-0.76], p<0.001; 
en test Z 70% [95% BI 0.57-0.83], p=0.016). Voor test Z ging dit gepaard met een daling in 
de specificiteit. Tenslotte laten onze resultaten zien dat de bestudeerde POC testen een 
verschillende sensitiviteit hebben voor het relatief laag-positieve TG2A in patiënten met 
behandelde coeliakie. De prestaties van de testen nemen mogelijk toe als de afleestijd van 
het resultaat verlengd wordt. Voordat POC testen toegepast worden in de follow-up van 
patiënten met behandelde coeliakie, raden wij aan een test te gebruiken die gevalideerd is 
voor deze specifieke patiëntenpopulatie.
Hoofdstuk 6 bevat de algemene discussie en de conclusie van dit proefschrift. Tevens 
zetten wij de toekomstperspectieven voor de preventie van coeliakie en de zorg voor 
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